

Table Q-1-3. (Continued)
Summary of Unadjusted Results for Continuous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter (units)	R ²	Dioxin Category	n	Mean ^a	Difference of Mean vs. Comparisons (95% C.I.)	p-Value
19-9	CD14 Cells (cells/mm ³) ^b	0.152	Comparison	404	523.5		
			Background RH	141	535.1	11.6 --	0.581
			Low RH	95	483.7	-39.8 --	0.033
			High RH	108	515.0	-8.5 --	0.586
			Low plus High RH	203	500.1	-23.4 --	0.092
19-10	CD16+56 Cells (cells/mm ³) ^b	0.140	Comparison	404	261.4		
			Background RH	141	254.8	-6.6 --	0.647
			Low RH	95	241.7	-19.7 --	0.232
			High RH	108	244.4	-17.0 --	0.277
			Low plus High RH	203	243.2	-18.2 --	0.143
19-11	CD20 Cells (cells/mm ³) ^f	0.010	Comparison	404	213.5		
			Background RH	141	228.9	15.4 --	0.203
			Low RH	95	210.8	-2.7 --	0.836
			High RH	108	235.4	21.9 --	0.105
			Low plus High RH	203	223.5	10.0 --	0.336
19-12	CD25 Cells (cells/mm ³) ^b	0.256	Comparison	404	248.8		
			Background RH	141	254.0	5.2 --	0.680
			Low RH	95	244.2	-4.6 --	0.753
			High RH	108	255.2	6.4 --	0.647
			Low plus High RH	203	250.0	1.2 --	0.913
19-13	CD4-CD8 Ratio ^b	0.008	Comparison	404	1.488		
			Background RH	141	1.504	0.016 --	0.799
			Low RH	95	1.541	0.053 --	0.470
			High RH	108	1.553	0.065 --	0.357
			Low plus High RH	203	1.548	0.060 --	0.286
19-14	Double Labelled Cells: CD3 with CD25 (cells/mm ³) ^b	0.241	Comparison	404	196.0		
			Background RH	141	201.1	5.1 --	0.635
			Low RH	95	193.7	-2.3 --	0.850
			High RH	108	202.0	6.0 --	0.614
			Low plus High RH	203	198.1	2.1 --	0.827

Table Q-1-3. (Continued)
Summary of Unadjusted Results for Continuous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter (units)	R ²	Dioxin Category	n	Mean ^a	Difference of Mean vs. Comparisons (95% C.I.)	p-Value
19-15	Double Labelled Cells: CD5 with CD20 (cells/mm ³) ^b (Nonzero Measurements)	0.122	Comparison	386	50.6		
			Background RH	137	49.8	-0.8 --	0.842
			Low RH	87	51.8	1.2 --	0.808
			High RH	104	59.2	8.6 --	0.084
			Low plus High RH	191	53.7	5.1 --	0.189
19-16	Double Labelled Cells: CD4 with CD8 (cells/mm ³) ^b (Nonzero Measurements)	0.007	Comparison	361	29.4		
			Background RH	126	31.7	2.35 --	0.283
			Low RH	85	26.4	-3.00 --	0.190
			High RH	95	27.9	-1.46 --	0.518
			Low plus High RH	180	27.2	-2.20 --	0.211
19-17	Double Labelled Cells: CD3 with CD16+56 (cells/mm ³) ^b (Nonzero Measurements)	0.153	Comparison	390	72.1		
			Background RH	137	78.8	6.7 --	0.355
			Low RH	93	78.3	6.2 --	0.458
			High RH	101	62.0	-10.1 --	0.158
			Low plus High RH	194	69.3	-2.8 --	0.645
19-18	TLC (cells/mm ³) ^b	0.141	Comparison	404	2,021.7		
			Background RH	141	2,059.2	37.5 --	0.587
			Low RH	95	1,956.9	-64.8 --	0.409
			High RH	108	2,065.1	43.4 --	0.568
			Low plus High RH	203	2,013.7	-8.0 --	0.894
19-19	IgA (mg/dl) ^b	0.005	Comparison	1,051	220.4		
			Background RH	367	216.5	-3.9 --	0.529
			Low RH	256	215.6	-4.8 --	0.490
			High RH	255	220.2	-0.2 --	0.987
			Low plus High RH	511	217.8	-2.6 --	0.648
19-20	IgG (mg/dl) ^b	0.004	Comparison	1,051	1,051.7		
			Background RH	367	1,030.4	-21.3 --	0.140
			Low RH	256	1,035.0	-16.8 --	0.310
			High RH	255	1,033.0	-18.7 --	0.258
			Low plus High RH	511	1,034.0	-17.7 --	0.165

Table Q-1-3. (Continued)
Summary of Unadjusted Results for Continuous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter (units)	R ²	Dioxin Category	n	Mean ^a	Difference of Mean vs. Comparisons (95% C.I.)	p-Value
19-21	IgM (mg/dl) ^b	0.005	Comparison	1,051	104.8		
			Background RH	367	105.4	0.6 --	0.863
			Low RH	256	102.7	-2.1 --	0.610
			High RH	255	103.4	-1.4 --	0.731
			Low plus High RH	511	103.1	-1.7 --	0.581
20-8	FVC (Percent of Predicted)	0.049	Comparison	1,062	100.5		
			Background RH	373	101.2	0.7 (-1.0,2.3)	0.439
			Low RH	260	99.2	-1.3 (-3.2,0.7)	0.196
			High RH	260	99.2	-1.3 (-3.2,0.6)	0.179
			Low plus High RH	520	99.2	-1.3 (-2.8,0.2)	0.089
20-9	FEV ₁ (Percent of Predicted)	0.003	Comparison	1,062	95.3		
			Background RH	373	94.6	-0.7 (-2.8,1.3)	0.492
			Low RH	260	93.9	-1.4 (-3.7,1.0)	0.257
			High RH	260	94.9	-0.4 (-2.8,2.0)	0.743
			Low plus High RH	520	94.4	-0.9 (-2.7,0.9)	0.345
20-10	Ratio of Observed FEV ₁ to Observed FVC ^c	0.052	Comparison	1,062	0.762		
			Background RH	373	0.750	-0.012 --	0.009
			Low RH	260	0.762	0.000 --	0.990
			High RH	260	0.774	0.012 --	0.022
			Low plus High RH	520	0.768	0.006 --	0.136

^a Adjusted for percent body fat at the time of duty in SEA and change in percent body fat at the time of duty in SEA to the date of the blood draw for dioxin.

^b Means transformed from natural logarithm scale; difference of means after transformation to original scale; confidence interval not given because analysis was performed on natural logarithm scale; p-value based on difference of means on natural logarithm scale.

^c Means transformed from natural logarithm (clinical parameter + 0.1) scale; difference of means after transformation to original scale; confidence interval not given because analysis was performed on natural logarithm (clinical parameter + 0.1) scale; p-value based on difference of means on natural logarithm (clinical parameter + 0.1) scale.

^d Means transformed from square root scale; difference of means after transformation to original scale; confidence interval not given because analysis was performed on square root scale; p-value based on difference of means on square root scale.

^e Coefficient and standard error for Ranch Hand versus Comparison contrast in a failure time analysis model, using a censored Weibull distribution.

^f Means transformed from natural logarithm (clinical parameter + 1) scale; difference of means after transformation to original scale; confidence interval not given because analysis was performed on natural logarithm (clinical parameter + 1) scale; p-value based on difference of means on natural logarithm (clinical parameter + 1) scale.

^g Means transformed from natural logarithm (1 - clinical parameter) scale; difference of means after transformation to original scale; confidence interval not given because analysis was performed on natural logarithm (1 - clinical parameter) scale; p-value based on difference of means on natural logarithm (1 - clinical parameter) scale.

Note: RH = Ranch Hand.

Comparison: Current Dioxin $\leq$ 10 ppt.

Background (Ranch Hand): Current Dioxin $\leq$ 10 ppt.

Low (Ranch Hand): Current Dioxin $>$ 10 ppt, 10 ppt $<$ Initial Dioxin $\leq$ 143 ppt.

High (Ranch Hand): Current Dioxin $>$ 10 ppt, Initial Dioxin $>$ 143 ppt.

Table Q-1-4.
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands – Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
9-6	Body Fat (Percent) ^b	4	0.086	0.0471 (0.0051)	<0.001
		5	0.096	0.0427 (0.0044)	<0.001
		6	0.092	0.0412 (0.0047)	<0.001
9-7	Body Fat (Percent) with Adjustment for Caloric Intake ^b	4	0.086	0.0471 (0.0051)	<0.001
		5	0.096	0.0427 (0.0044)	<0.001
		6	0.092	0.0412 (0.0047)	<0.001
9-10	Sedimentation Rate (mm/hr) ^c	4	0.007	0.0490 (0.0199)	0.014
		5	0.011	0.0541 (0.0170)	0.001
		6	0.029	0.0309 (0.0182)	0.090
10-40	Prostate-Specific Antigen (ng/ml) ^b (Measurements at or Above Sensitivity Limit)	4	0.009	-0.049 (0.017)	0.005
		5	0.009	-0.042 (0.015)	0.005
		6	0.010	-0.041 (0.016)	0.010
11-28	Vibrotactile Threshold Measurement of Right Great Toe (microns) ^b	4	<0.001	0.0017 (0.0271)	0.950
		5	<0.001	0.0067 (0.0232)	0.772
		6	0.002	-0.0082 (0.0251)	0.744
11-29	Vibrotactile Threshold Measurement of Left Great Toe (microns) ^b	4	<0.001	-0.0106 (0.0274)	0.698
		5	<0.001	-0.0056 (0.0235)	0.813
		6	0.001	-0.0150 (0.0254)	0.557
13-12	AST (U/L) ^b	4	0.002	0.0116 (0.0084)	0.166
		5	0.003	0.0120 (0.0072)	0.095
		6	0.005	0.0088 (0.0077)	0.253
13-14	ALT (U/L) ^b	4	0.023	0.0476 (0.0104)	<0.001
		5	0.025	0.0429 (0.0090)	<0.001
		6	0.025	0.0410 (0.0097)	<0.001
13-16	GGT (U/L) ^b	4	0.018	0.0578 (0.0142)	<0.001
		5	0.027	0.0604 (0.0122)	<0.001
		6	0.051	0.0395 (0.0130)	0.002
13-18	Alkaline Phosphatase (U/L) ^b	4	0.001	0.0063 (0.0059)	0.286
		5	0.001	0.0056 (0.0050)	0.266
		6	0.007	0.0024 (0.0054)	0.665
13-20	Total Bilirubin (mg/dl) ^b	4	0.001	-0.0088 (0.0093)	0.343
		5	<0.001	-0.0041 (0.0080)	0.607
		6	0.003	-0.0093 (0.0086)	0.281
13-23	LDH (U/L) ^b	4	0.002	0.0049 (0.0039)	0.211
		5	0.002	0.0042 (0.0033)	0.208
		6	0.002	0.0034 (0.0036)	0.341
13-25	Cholesterol (mg/dl) ^b	4	0.002	0.0058 (0.0041)	0.162
		5	0.019	0.0145 (0.0035)	<0.001
		6	0.272	-0.0054 (0.0033)	0.098

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands – Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
13-27	HDL Cholesterol (mg/dl) ^b	4	0.022	-0.0269 (0.0061)	<0.001
		5	0.027	-0.0255 (0.0052)	<0.001
		6	0.041	-0.0187 (0.0055)	0.001
13-29	Cholesterol-HDL Ratio ^b	4	0.024	0.0312 (0.0068)	<0.001
		5	0.049	0.0384 (0.0058)	<0.001
		6	0.226	0.0118 (0.0056)	0.035
13-31	Triglycerides (mg/dl) ^b	4	0.027	0.0649 (0.0130)	<0.001
		5	0.066	0.0888 (0.0109)	<0.001
		6	0.380	0.0196 (0.0096)	0.041
13-33	Creatine Kinase (U/L) ^b	4	0.006	0.0278 (0.0116)	0.017
		5	0.007	0.0253 (0.0100)	0.011
		6	0.006	0.0237 (0.0107)	0.027
13-35	Serum Amylase (U/L) ^b	4	0.005	-0.0171 (0.0082)	0.037
		5	0.006	-0.0164 (0.0070)	0.019
		6	0.011	-0.0104 (0.0075)	0.170
13-41	Prealbumin (mg/dl)	4	<0.001	-0.0193 (0.1040)	0.853
		5	0.001	0.0977 (0.0893)	0.274
		6	0.029	-0.0968 (0.0947)	0.307
13-43	Albumin (mg/dl)	4	<0.001	2.7200 (6.9959)	0.698
		5	0.001	4.4671 (6.0070)	0.457
		6	0.004	0.4077 (6.4688)	0.950
13-45	α -1 Acid Glycoprotein (mg/dl) ^b	4	0.004	0.0093 (0.0049)	0.060
		5	0.007	0.0103 (0.0042)	0.015
		6	0.021	0.0055 (0.0045)	0.221
13-47	α -1 Antitrypsin (mg/dl)	4	<0.001	-0.3957 (0.6371)	0.535
		5	0.001	-0.6233 (0.5469)	0.255
		6	0.001	-0.2962 (0.5870)	0.614
13-49	α -2 Macroglobulin (mg/dl) ^b	4	0.005	-0.0111 (0.0051)	0.029
		5	0.005	-0.0087 (0.0043)	0.046
		6	0.008	-0.0111 (0.0047)	0.018
13-51	Apolipoprotein B (mg/dl) ^b	4	0.007	0.0138 (0.0057)	0.016
		5	0.028	0.0244 (0.0048)	<0.001
		6	0.271	-0.0022 (0.0045)	0.624
13-53	C ₃ Complement (mg/dl) ^b	4	0.051	0.0232 (0.0034)	<0.001
		5	0.073	0.0240 (0.0029)	<0.001
		6	0.119	0.0160 (0.0030)	<0.001
13-55	C ₄ Complement (mg/dl) ^b	4	0.004	0.0102 (0.0056)	0.068
		5	0.009	0.0138 (0.0048)	0.004
		6	0.041	0.0038 (0.0051)	0.452

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands -- Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
13-57	Haptoglobin (mg/dl)	4	0.002	1.3757 (1.0196)	0.178
		5	0.003	1.3748 (0.8754)	0.117
		6	0.010	0.7333 (0.9404)	0.436
13-59	Transferrin (mg/dl) ^b	4	0.007	0.0101 (0.0031)	0.001
		5	0.018	0.0108 (0.0027)	<0.001
		6	0.030	0.0074 (0.0028)	0.009
15-6	Systolic Blood Pressure (mm Hg)	4	0.004	0.777 (0.424)	0.067
		5	0.007	0.884 (0.365)	0.016
		6	0.009	0.616 (0.394)	0.119
15-18	Diastolic Blood Pressure (mm Hg)	4	0.009	0.643 (0.228)	0.005
		5	0.013	0.656 (0.196)	0.001
		6	0.016	0.492 (0.212)	0.020
16-3	Red Blood Cell (RBC) Count (million/mm ³)	4	0.004	0.0162 (0.0089)	0.072
		5	0.005	0.0157 (0.0077)	0.042
		6	0.008	0.0109 (0.0083)	0.188
16-5	White Blood Cell (WBC) Count (thousand/mm ³) ^b	4	0.002	0.0093 (0.0066)	0.162
		5	0.003	0.0086 (0.0057)	0.130
		6	0.013	0.0035 (0.0061)	0.571
16-7	Hemoglobin (gm/dl)	4	0.001	0.0237 (0.0244)	0.332
		5	0.002	0.0250 (0.0209)	0.232
		6	0.008	0.0088 (0.0225)	0.696
16-9	Hematocrit (percent)	4	0.001	0.0827 (0.0747)	0.268
		5	0.002	0.0827 (0.0640)	0.197
		6	0.006	0.0397 (0.0691)	0.565
16-11	Platelet Count (thousand/mm ³) ^d	4	0.005	0.0845 (0.0395)	0.033
		5	0.006	0.0800 (0.0339)	0.018
		6	0.009	0.0734 (0.0366)	0.045
16-13	Prothrombin Time (seconds) ^b	4	<0.001	-0.0002 (0.0009)	0.819
		5	0.001	-0.0007 (0.0008)	0.412
		6	0.011	0.0002 (0.0009)	0.814
16-16	Absolute Neutrophils (segs) (thousand/mm ³) ^b	4	0.003	0.0135 (0.0086)	0.116
		5	0.003	0.0120 (0.0074)	0.104
		6	0.010	0.0069 (0.0079)	0.387
16-17	Absolute Neutrophils (bands) (thousand/mm ³) ^b (Nonzero Measurements)	4	<0.001	-0.0108 (0.0201)	0.592
		5	<0.001	-0.0071 (0.0171)	0.679
		6	0.008	-0.0246 (0.0185)	0.185
16-18	Absolute Lymphocytes (thousand/mm ³) ^b	4	<0.001	0.0052 (0.0086)	0.549
		5	0.001	0.0055 (0.0074)	0.461
		6	0.006	0.0006 (0.0080)	0.939

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands – Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
16-19	Absolute Monocytes (thousand/mm ³) ^d	4	0.002	0.0054 (0.0041)	0.191
		5	0.002	0.0046 (0.0035)	0.190
		6	0.002	0.0040 (0.0038)	0.297
16-20	Absolute Eosinophils (thousand/mm ³) ^b (Nonzero Measurements)	4	0.002	-0.0243 (0.0181)	0.180
		5	0.002	-0.0206 (0.0154)	0.182
		6	0.003	-0.0264 (0.0166)	0.113
16-21	Absolute Basophils (thousand/mm ³) ^b (Nonzero Measurements)	4	<0.001	0.0056 (0.0143)	0.695
		5	<0.001	0.0060 (0.0123)	0.624
		6	0.013	-0.0062 (0.0132)	0.640
17-8	Serum Creatinine (mg/dl) ^b	4	<0.001	0.0011 (0.0042)	0.797
		5	<0.001	0.0021 (0.0036)	0.571
		6	<0.001	0.0007 (0.0039)	0.863
17-9	Urine Specific Gravity	4	0.007	0.0004 (0.0001)	0.013
		5	0.008	0.0003 (0.0001)	0.007
		6	0.008	0.0003 (0.0001)	0.027
18-6	Time to Diabetes Onset (years) ^e	4	--	-0.0694 (0.0238)	0.004
		5	--	-0.0734 (0.0216)	0.001
		6	--	-0.0506 (0.0228)	0.026
18-8	Testicular Volume: Minimum (cm ³)	4	<0.001	-0.0782 (0.1307)	0.550
		5	<0.001	-0.0285 (0.1122)	0.799
		6	0.002	-0.0880 (0.1211)	0.467
18-9	Testicular Volume: Total (cm ³) ^d	4	0.001	-0.0175 (0.0220)	0.426
		5	<0.001	-0.0094 (0.0189)	0.618
		6	0.002	-0.0194 (0.0204)	0.341
18-19	Thyroid Stimulating Hormone (TSH) (μIU/ml) ^b	4	<0.001	0.0087 (0.0145)	0.547
		5	0.001	0.0120 (0.0124)	0.334
		6	0.003	0.0060 (0.0134)	0.655
18-21	Thyroxine (T ₄) (μg/dl)	4	0.003	0.0532 (0.0308)	0.085
		5	0.002	0.0384 (0.0264)	0.147
		6	0.003	0.0469 (0.0286)	0.101
18-24	Fasting Glucose (mg/dl) ^b (All Participants)	4	0.018	0.0185 (0.0046)	<0.001
		5	0.026	0.0193 (0.0039)	<0.001
		6	0.053	0.0116 (0.0042)	0.005
18-26	Fasting Glucose (mg/dl) ^b (Diabetics)	4	0.072	0.0603 (0.0185)	0.001
		5	0.089	0.0558 (0.0153)	<0.001
		6	0.117	0.0389 (0.0172)	0.025
18-28	Fasting Glucose (mg/dl) ^b (Nondiabetics)	4	<0.001	-0.0002 (0.0022)	0.943
		5	<0.001	0.0009 (0.0019)	0.650
		6	0.006	-0.0009 (0.0020)	0.656

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands -- Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
18-30	2-Hour Postprandial Glucose (mg/dl) ^b (Nondiabetics)	4	0.018	0.0267 (0.0071)	<0.001
		5	0.026	0.0275 (0.0061)	<0.001
		6	0.037	0.0214 (0.0065)	0.001
18-36	Serum Insulin (mIU/ml) ^b (All Participants)	4	0.113	0.0989 (0.0205)	<0.001
		5	0.122	0.1008 (0.0175)	<0.001
		6	0.140	0.0726 (0.0186)	<0.001
18-38	Serum Insulin (mIU/ml) ^b (Diabetics)	4	0.478	-0.0442 (0.0501)	0.380
		5	0.478	-0.0325 (0.0418)	0.438
		6	0.478	-0.0337 (0.0473)	0.477
18-40	Serum Insulin (mIU/ml) ^b (Nondiabetics)	4	0.044	0.1259 (0.0218)	<0.001
		5	0.059	0.1263 (0.0187)	<0.001
		6	0.089	0.0960 (0.0196)	<0.001
18-42	Serum Glucagon (pg/ml) ^b (All Participants)	4	0.051	0.0111 (0.0062)	0.073
		5	0.054	0.0120 (0.0053)	0.023
		6	0.057	0.0084 (0.0057)	0.140
18-44	Serum Glucagon (pg/ml) ^b (Diabetics)	4	0.015	-0.0070 (0.0184)	0.705
		5	0.014	0.0009 (0.0153)	0.952
		6	0.029	-0.0093 (0.0171)	0.587
18-46	Serum Glucagon (pg/ml) ^b (Nondiabetics)	4	0.008	0.0143 (0.0064)	0.025
		5	0.009	0.0136 (0.0055)	0.013
		6	0.010	0.0117 (0.0059)	0.047
18-48	α -1-C Hemoglobin (percent) ^b (All Participants)	4	0.011	0.0123 (0.0038)	0.001
		5	0.016	0.0126 (0.0033)	<0.001
		6	0.036	0.0072 (0.0035)	0.042
18-50	α -1-C Hemoglobin (percent) ^b (Diabetics)	4	0.048	0.0391 (0.0149)	0.010
		5	0.050	0.0334 (0.0124)	0.008
		6	0.064	0.0241 (0.0141)	0.090
18-52	α -1-C Hemoglobin (percent) ^b (Nondiabetics)	4	<0.001	-0.0011 (0.0023)	0.625
		5	<0.001	-0.0002 (0.0020)	0.926
		6	0.005	-0.0015 (0.0021)	0.457
18-55	Serum Proinsulin (ng/ml) ^d (Diabetics)	4	0.363	0.032 (0.020)	0.113
		5	0.370	0.033 (0.016)	0.047
		6	0.382	0.020 (0.018)	0.288
18-57	Serum C Peptide (ng/ml) (Diabetics)	4	0.617	0.140 (0.240)	0.561
		5	0.617	0.138 (0.200)	0.489
		6	0.618	0.188 (0.226)	0.408
18-59	Total Testosterone (ng/dl) ^d	4	0.023	-0.4277 (0.0951)	<0.001
		5	0.035	-0.4561 (0.0811)	<0.001
		6	0.042	-0.3385 (0.0870)	<0.001

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands -- Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
18-61	Free Testosterone (pg/ml) ^d	4	0.001	-0.014 (0.016)	0.383
		5	<0.001	-0.008 (0.014)	0.546
		6	0.001	-0.003 (0.015)	0.818
18-65	Estradiol (pg/ml) ^d	4	0.002	0.034 (0.027)	0.198
		5	0.002	0.028 (0.023)	0.226
		6	0.004	0.020 (0.025)	0.418
18-67	Luteinizing Hormone (LH) (mIU/ml) ^b	4	0.005	-0.024 (0.012)	0.035
		5	0.004	-0.019 (0.010)	0.052
		6	0.005	-0.023 (0.011)	0.035
18-69	Follicle Stimulating Hormone (FSH) (mIU/ml) ^b	4	0.001	-0.014 (0.016)	0.383
		5	<0.001	-0.006 (0.013)	0.640
		6	0.004	-0.018 (0.014)	0.226
19-5	CD3 Cells (cells/mm ³) ^b	4	0.296	-0.002 (0.017)	0.896
		5	0.296	-0.001 (0.015)	0.967
		6	0.300	-0.008 (0.016)	0.629
19-6	CD4 Cells (cells/mm ³) ^b	4	0.269	0.001 (0.017)	0.974
		5	0.269	0.003 (0.015)	0.866
		6	0.276	-0.007 (0.016)	0.647
19-7	CD5 Cells (cells/mm ³) ^b	4	0.282	0.003 (0.017)	0.865
		5	0.282	0.004 (0.015)	0.802
		6	0.285	-0.003 (0.016)	0.838
19-8	CD8 Cells (cells/mm ³) ^b	4	0.001	-0.009 (0.019)	0.639
		5	0.001	-0.009 (0.016)	0.592
		6	0.001	-0.009 (0.018)	0.602
19-9	CD14 Cells (cells/mm ³) ^b	4	0.241	-0.004 (0.014)	0.767
		5	0.240	0.000 (0.012)	0.985
		6	0.256	-0.012 (0.013)	0.383
19-10	CD16+56 Cells (cells/mm ³) ^b	4	0.241	-0.007 (0.024)	0.766
		5	0.241	-0.009 (0.020)	0.669
		6	0.241	-0.006 (0.022)	0.793
19-11	CD20 Cells (cells/mm ³) ^f	4	0.003	0.022 (0.020)	0.280
		5	0.004	0.021 (0.018)	0.250
		6	0.006	0.014 (0.019)	0.473
19-12	CD25 Cells (cells/mm ³) ^b	4	0.363	-0.004 (0.021)	0.848
		5	0.363	-0.001 (0.019)	0.960
		6	0.370	-0.014 (0.020)	0.482
19-13	CD4-CD8 Ratio ^b	4	0.001	0.011 (0.016)	0.510
		5	0.003	0.014 (0.014)	0.338
		6	0.013	0.003 (0.015)	0.833

Table Q-1-4. (Continued)
Summary of Unadjusted Results for Continuous Variables
Models 4, 5, and 6: Ranch Hands -- Log₂ (Current Dioxin + 1)

Table Ref.	Clinical Parameter (units)	Model ^a	R ²	Slope (Std. Error)	p-Value
19-14	Double Labelled Cells: CD3 with CD25 (cells/mm ³) ^b	4	0.365	-0.007 (0.023)	0.750
		5	0.365	-0.004 (0.020)	0.859
		6	0.372	-0.018 (0.022)	0.414
19-15	Double Labelled Cells: CD5 with CD20 (cells/mm ³) ^b (Nonzero Measurements)	4	0.274	0.078 (0.033)	0.017
		5	0.275	0.069 (0.028)	0.016
		6	0.276	0.062 (0.031)	0.044
19-16	Double Labelled Cells: CD4 with CD8 (cells/mm ³) ^b (Nonzero Measurements)	4	0.002	-0.021 (0.027)	0.443
		5	0.001	-0.021 (0.041)	0.614
		6	0.001	-0.028 (0.044)	0.522
19-17	Double Labelled Cells: CD3 with CD16+56 (cells/mm ³) ^b (Nonzero Measurements)	4	0.302	-0.102 (0.041)	0.014
		5	0.304	-0.093 (0.035)	0.009
		6	0.308	-0.074 (0.038)	0.053
19-18	TLC (cells/mm ³) ^b	4	0.269	0.005 (0.014)	0.702
		5	0.270	0.005 (0.012)	0.657
		6	0.274	-0.001 (0.013)	0.957
19-19	IgA (mg/dl) ^b	4	0.002	0.013 (0.011)	0.218
		5	0.001	0.007 (0.009)	0.455
		6	0.006	0.016 (0.010)	0.099
19-20	IgG (mg/dl) ^b	4	0.001	0.004 (0.005)	0.508
		5	<0.001	-0.001 (0.005)	0.892
		6	0.012	0.005 (0.005)	0.290
19-21	IgM (mg/dl) ^b	4	<0.001	0.001 (0.013)	0.914
		5	<0.001	-0.002 (0.011)	0.825
		6	0.005	0.005 (0.012)	0.698
20-8	FVC (Percent of Predicted)	4	0.011	-1.023 (0.323)	0.002
		5	0.012	-0.919 (0.277)	0.001
		6	0.016	-0.728 (0.299)	0.015
20-9	FEV ₁ (Percent of Predicted)	4	<0.001	0.231 (0.405)	0.568
		5	<0.001	0.107 (0.347)	0.757
		6	0.008	0.437 (0.374)	0.243
20-10	Ratio of Observed FEV ₁ to Observed FVC ^c	4	0.041	-0.046 (0.007)	<0.001
		5	0.035	-0.037 (0.006)	<0.001
		6	0.042	-0.043 (0.007)	<0.001

^a Model 4: Log₂ (lipid-adjusted current dioxin + 1).
Model 5: Log₂ (whole-weight current dioxin + 1).
Model 6: Log₂ (whole-weight current dioxin + 1), adjusted for log₂ total lipids.

^b Slope and standard error based on natural logarithm of clinical parameter versus log₂ (current dioxin + 1).

^c Slope and standard error based on natural logarithm of (clinical parameter + 0.1) versus log₂ (current dioxin + 1).

^d Slope and standard error based on square root of clinical parameter versus $\log_2$ (current dioxin + 1).

^e Slope and standard error based on time to diabetes onset versus $\log_2$ (current dioxin + 1) under a censored Weibull distribution.

^f Slope and standard error based on natural logarithm of (clinical parameter + 1) versus $\log_2$ (current dioxin + 1).

^g Slope and standard error based on natural logarithm of (1 - clinical parameter) versus $\log_2$ (current dioxin + 1).

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
10-6	Skin Neoplasms of Uncertain Behavior or Unspecified Nature	All	0.5	0.6	0.77 (0.23,2.64)	0.914
		Officer	0.6	0.6	0.92 (0.15,5.50)	0.999
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.5	0.8	0.69 (0.13,3.76)	0.982
10-7	Basal Cell Carcinomas (All Sites Combined)	All	11.3	10.2	1.12 (0.85,1.49)	0.462
		Officer	15.1	12.9	1.21 (0.82,1.79)	0.399
		Enlisted Flyer	13.3	11.2	1.22 (0.63,2.34)	0.675
		Enlisted Ground.	6.9	7.3	0.94 (0.56,1.57)	0.906
10-8	Basal Cell Carcinomas (Ear, Face, Head, and Neck)	All	9.1	7.9	1.18 (0.87,1.61)	0.330
		Officer	12.0	9.4	1.32 (0.85,2.05)	0.258
		Enlisted Flyer	10.7	9.6	1.12 (0.55,2.28)	0.894
		Enlisted Ground.	5.8	5.8	1.01 (0.57,1.78)	0.999
10-9	Basal Cell Carcinomas (Trunk)	All	3.5	3.0	1.17 (0.72,1.91)	0.613
		Officer	5.6	4.7	1.21 (0.65,2.23)	0.663
		Enlisted Flyer	4.0	2.1	1.91 (0.53,6.88)	0.498
		Enlisted Ground.	1.3	1.7	0.76 (0.25,2.29)	0.829
10-10	Basal Cell Carcinomas (Upper Extremities)	All	1.9	1.7	1.15 (0.60,2.21)	0.796
		Officer	3.6	2.7	1.39 (0.64,3.03)	0.534
		Enlisted Flyer	0.7	0.5	1.25 (0.08,20.13)	0.999
		Enlisted Ground.	0.8	1.2	0.69 (0.17,2.76)	0.844
10-11	Basal Cell Carcinomas (Lower Extremities)	All	0.1	0.3	0.45 (0.05,4.33)	0.839
		Officer	0.3	0.2	1.37 (0.09,22.03)	0.999
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.4	--	--
10-12	Squamous Cell Carcinomas	All	1.4	1.2	1.16 (0.53,2.52)	0.859
		Officer	1.7	1.8	0.91 (0.32,2.59)	0.999
		Enlisted Flyer	1.3	1.1	1.25 (0.17,8.98)	0.999
		Enlisted Ground.	1.1	0.6	1.84 (0.41,8.28)	0.671
10-13	Nonmelanomas	All	12.6	11.3	1.14 (0.87,1.49)	0.374
		Officer	17.1	14.5	1.22 (0.84,1.77)	0.351
		Enlisted Flyer	14.7	12.3	1.23 (0.65,2.30)	0.636
		Enlisted Ground.	7.7	7.9	0.97 (0.59,1.59)	0.999
10-14	Melanomas	All	1.2	0.8	1.49 (0.63,3.53)	0.486
		Officer	1.7	1.0	1.66 (0.50,5.48)	0.596
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	1.3	1.0	1.38 (0.40,4.80)	0.852

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
10-15	Systemic Neoplasms	All	21.1	20.5	1.04 (0.85,1.28)	0.755
		Officer	21.3	22.9	0.91 (0.66,1.27)	0.640
		Enlisted Flyer	24.4	22.2	1.13 (0.69,1.85)	0.712
		Enlisted Ground.	19.7	17.7	1.14 (0.82,1.57)	0.489
10-16	Malignant Systemic Neoplasms	All	5.0	4.3	1.17 (0.78,1.74)	0.507
		Officer	6.1	6.4	0.95 (0.54,1.67)	0.980
		Enlisted Flyer	8.1	5.4	1.54 (0.67,3.54)	0.414
		Enlisted Ground.	2.8	2.1	1.37 (0.61,3.09)	0.575
10-17	Benign Systemic Neoplasms	All	16.4	15.6	1.07 (0.85,1.34)	0.611
		Officer	14.1	16.1	0.86 (0.59,1.25)	0.476
		Enlisted Flyer	19.4	17.2	1.15 (0.68,1.97)	0.699
		Enlisted Ground.	17.3	14.4	1.24 (0.88,1.75)	0.254
10-18	Systemic Neoplasms of Uncertain Behavior or Unspecified Nature	All	1.6	1.7	0.92 (0.48,1.79)	0.948
		Officer	2.8	2.2	1.27 (0.53,3.03)	0.749
		Enlisted Flyer	0.0	1.0	--	--
		Enlisted Ground.	1.2	1.6	0.75 (0.25,2.27)	0.817
10-19	Malignant Systemic Neoplasms (Eye, Ear, Face, Head, and Neck)	All	1.1	0.8	1.36 (0.56,3.28)	0.644
		Officer	1.4	0.6	2.34 (0.56,9.84)	0.406
		Enlisted Flyer	1.3	2.0	0.63 (0.11,3.48)	0.905
		Enlisted Ground.	0.7	0.5	1.37 (0.27,6.80)	0.999
10-20	Malignant Systemic Neoplasms (Oral Cavity, Pharynx, and Larynx)	All	0.4	0.5	0.91 (0.26,3.21)	0.999
		Officer	0.3	0.4	0.69 (0.06,7.69)	0.999
		Enlisted Flyer	1.3	1.0	1.27 (0.18,9.13)	0.999
		Enlisted Ground.	0.2	0.4	0.68 (0.06,7.53)	0.999
10-21	Malignant Systemic Neoplasms (Esophagus)	All	0.0	0.1	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.5	--	--
		Enlisted Ground.	0.0	0.0	--	--
10-22	Malignant Systemic Neoplasms (Brain)	All	0.1	0.1	1.35 (0.09,21.74)	0.999
		Officer	0.3	0.0	--	--
		Enlisted Flyer	0.0	0.5	--	--
		Enlisted Ground.	0.0	0.0	--	--
10-23	Malignant Systemic Neoplasms (Thymus, Heart, and Mediastinum)	All	0.2	0.0	--	--
		Officer	0.3	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RE	C		
10-24	Malignant Systemic Neoplasms (Thyroid Gland)	All	0.2	0.2	1.36 (0.19,9.66)	0.999
		Officer	0.6	0.2	2.80 (0.25,30.90)	0.774
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--
10-25	Malignant Systemic Neoplasms (Bronchus and Lung)	All	0.6	0.3	2.04 (0.58,7.26)	0.420
		Officer	1.1	0.2	5.61 (0.63,50.43)	0.200
		Enlisted Flyer	0.6	1.0	0.63 (0.06,7.03)	0.999
		Enlisted Ground.	0.2	0.2	1.36 (0.09,21.86)	0.999
10-26	Malignant Systemic Neoplasms (Colon and Rectum)	All	0.5	0.3	1.70 (0.46,6.35)	0.645
		Officer	0.8	0.6	1.39 (0.28,6.95)	0.999
		Enlisted Flyer	1.3	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--
10-27	Malignant Systemic Neoplasms (Kidney and Bladder)	All	0.6	0.4	1.63 (0.50,5.37)	0.610
		Officer	0.8	1.0	0.83 (0.20,3.51)	0.999
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.5	0.0	--	--
10-28	Malignant Systemic Neoplasms (Prostate)	All	1.7	1.8	0.94 (0.50,1.80)	0.989
		Officer	2.5	3.2	0.78 (0.34,1.78)	0.694
		Enlisted Flyer	2.5	2.0	1.28 (0.31,5.18)	0.999
		Enlisted Ground.	0.7	0.5	1.37 (0.27,6.80)	0.999
10-29	Malignant Systemic Neoplasms (Testicles)	All	0.3	0.0	--	--
		Officer	0.3	0.0	--	--
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
10-30	Malignant Systemic Neoplasms (Ill-Defined Sites)	All	0.1	0.2	0.45 (0.05,4.35)	0.842
		Officer	0.0	0.4	--	--
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--
10-31	Malignant Systemic Neoplasms (Connective and Other Soft Tissue)	All	0.0	0.2	--	--
		Officer	0.0	0.2	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--
10-32	Carcinomas in Situ of the Penis, Other, and Unspecified Sites	All	0.1	0.1	1.36 (0.09,21.74)	0.999
		Officer	0.3	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
10-33	Hodgkin's Disease	All	0.1	0.1	1.36 (0.09,21.52)	0.999
		Officer	0.3	0.2	1.39 (0.09,22.32)	0.999
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.0	--	--
10-34	Leukemia	All	0.1	0.1	1.36 (0.09,21.74)	0.999
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.0	0.2	--	--
10-35	Non-Hodgkin's Lymphoma	All	0.1	0.3	0.34 (0.04,3.04)	0.574
		Officer	0.0	0.6	--	--
		Enlisted Flyer	0.0	0.5	--	--
		Enlisted Ground.	0.2	0.0	--	--
10-36	Other Malignant Systemic Neoplasms of Lymphoid and Histiocytic Tissue	All	0.1	0.1	1.36 (0.09,21.74)	0.999
		Officer	0.0	0.2	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
10-37	Multiple Myeloma	All	0.1	0.0	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
10-38	Skin or Systemic Neoplasms	All	44.9	41.4	1.16 (0.97,1.37)	0.108
		Officer	48.0	46.4	1.07 (0.82,1.40)	0.679
		Enlisted Flyer	48.1	43.1	1.23 (0.81,1.86)	0.398
		Enlisted Ground.	41.0	36.5	1.21 (0.94,1.57)	0.167
10-39	Prostate-Specific Antigen (Below vs. At or Above Sensitivity Limit)	All	2.4	2.9	0.84 (0.50,1.42)	0.603
		Officer	2.8	3.8	0.72 (0.33,1.58)	0.532
		Enlisted Flyer	2.5	1.5	1.70 (0.38,7.71)	0.755
		Enlisted Ground.	2.1	2.6	0.81 (0.35,1.88)	0.783
10-41	Prostate-Specific Antigen	All	3.6	4.9	0.73 (0.48,1.13)	0.188
		Officer	5.0	5.8	0.86 (0.47,1.57)	0.724
		Enlisted Flyer	5.0	6.9	0.71 (0.29,1.73)	0.588
		Enlisted Ground.	1.9	3.3	0.57 (0.25,1.30)	0.248
11-3	Inflammatory Diseases	All	0.6	0.2	4.05 (0.82,20.09)	0.136
		Officer	0.5	0.2	2.72 (0.25,30.09)	0.792
		Enlisted Flyer	1.2	0.0	--	0.388
		Enlisted Ground.	0.5	0.2	2.76 (0.25,30.48)	0.782

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
11-4	Hereditary and Degenerative Diseases	All	5.6	5.2	1.09 (0.75,1.58)	0.725
		Officer	4.9	4.6	1.07 (0.57,2.01)	0.963
		Enlisted Flyer	5.6	7.4	0.74 (0.31,1.73)	0.624
		Enlisted Ground.	6.2	4.9	1.30 (0.75,2.24)	0.434
11-5	Peripheral Disorders	All	16.9	15.9	1.08 (0.86,1.35)	0.552
		Officer	18.3	15.6	1.21 (0.85,1.73)	0.343
		Enlisted Flyer	18.0	17.3	1.05 (0.61,1.80)	0.975
		Enlisted Ground.	15.3	15.6	0.98 (0.69,1.38)	0.963
11-6	Other Neurological Disorders	All	21.2	19.2	1.14 (0.92,1.40)	0.258
		Officer	8.5	8.2	1.04 (0.64,1.69)	0.976
		Enlisted Flyer	31.5	29.7	1.09 (0.70,1.70)	0.801
		Enlisted Ground.	28.3	25.0	1.18 (0.89,1.57)	0.276
11-7	Smell	All	1.5	1.3	1.11 (0.55,2.27)	0.910
		Officer	1.1	1.8	0.60 (0.18,1.97)	0.573
		Enlisted Flyer	1.9	1.5	1.26 (0.25,6.32)	0.999
		Enlisted Ground.	1.7	0.9	1.94 (0.61,6.16)	0.395
11-8	Visual Fields	All	0.1	0.2	0.45 (0.05,4.32)	0.837
		Officer	0.0	0.4	--	0.619
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.2	1.38 (0.09,22.05)	0.999
11-9	Light Reaction	All	0.5	0.2	2.26 (0.54,9.47)	0.433
		Officer	0.3	0.4	0.68 (0.06,7.54)	0.999
		Enlisted Flyer	0.0	0.5	--	0.999
		Enlisted Ground.	1.0	0.0	--	0.066
11-10	Ocular Movement	All	0.7	0.5	1.58 (0.53,4.71)	0.586
		Officer	0.8	0.8	1.02 (0.23,4.60)	0.999
		Enlisted Flyer	0.6	0.0	--	0.910
		Enlisted Ground.	0.7	0.3	2.07 (0.34,12.43)	0.721
11-11	Facial Sensation	All	0.3	0.1	4.06 (0.42,39.10)	0.419
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.5	--	0.999
		Enlisted Ground.	0.7	0.0	--	0.148
11-12	Jaw Clench	All	0.1	0.0	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
11-13	Smile	All	0.9	0.6	1.52 (0.59,3.97)	0.533
		Officer	0.8	1.4	0.58 (0.15,2.26)	0.639
		Enlisted Flyer	0.6	0.0	--	0.910
		Enlisted Ground.	1.2	0.2	6.94 (0.81,59.66)	0.102
11-14	Palpebral Fissure	All	1.0	0.9	1.01 (0.43,2.41)	0.999
		Officer	0.8	1.2	0.68 (0.17,2.74)	0.836
		Enlisted Flyer	1.2	0.5	2.53 (0.23,28.10)	0.844
		Enlisted Ground.	1.0	0.9	1.01 (0.29,4.12)	0.999
11-15	Balance	All	0.5	0.5	1.13 (0.34,3.70)	0.999
		Officer	0.5	0.4	1.37 (0.19,9.76)	0.999
		Enlisted Flyer	0.0	1.5	--	0.332
		Enlisted Ground.	0.7	0.2	4.15 (0.43,40.01)	0.408
11-16	Gag Reflex	All	0.1	0.0	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
11-17	Speech	All	0.6	0.2	4.07 (0.82,20.21)	0.133
		Officer	0.3	0.2	1.37 (0.09,21.91)	0.999
		Enlisted Flyer	0.6	0.0	--	0.910
		Enlisted Ground.	1.0	0.2	5.54 (0.62,49.77)	0.205
11-18	Palate and Uvula Movement	All	0.1	0.0	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
11-19	Neck Range of Motion	All	14.4	13.9	1.04 (0.82,1.32)	0.808
		Officer	18.3	15.8	1.19 (0.83,1.71)	0.381
		Enlisted Flyer	14.2	20.7	0.63 (0.36,1.11)	0.141
		Enlisted Ground.	11.0	9.9	1.13 (0.75,1.70)	0.645
11-20	Cranial Nerve Index Without Range of Motion	All	4.6	3.5	1.30 (0.85,2.00)	0.266
		Officer	3.8	4.4	0.86 (0.44,1.71)	0.801
		Enlisted Flyer	3.1	4.4	0.69 (0.23,2.09)	0.695
		Enlisted Ground.	5.8	2.4	2.44 (1.25,4.78)	0.012
11-21	Pin Prick	All	5.5	5.4	1.02 (0.70,1.48)	0.999
		Officer	5.5	5.5	0.99 (0.54,1.82)	0.999
		Enlisted Flyer	5.1	8.7	0.57 (0.24,1.35)	0.275
		Enlisted Ground.	5.7	4.2	1.38 (0.76,2.50)	0.359

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
11-22	Light Touch	All	5.1	3.9	1.33 (0.88,2.01)	0.217
		Officer	4.6	4.2	1.09 (0.56,2.14)	0.934
		Enlisted Flyer	4.5	4.1	1.10 (0.39,3.10)	0.999
		Enlisted Ground.	5.7	3.5	1.68 (0.90,3.14)	0.134
11-23	Muscle Status	All	3.4	2.6	1.32 (0.80,2.16)	0.331
		Officer	3.3	2.2	1.51 (0.66,3.45)	0.448
		Enlisted Flyer	3.1	5.0	0.61 (0.20,1.82)	0.526
		Enlisted Ground.	3.6	2.1	1.75 (0.81,3.77)	0.216
11-24	Patellar Reflex	All	1.3	2.6	0.48 (0.25,0.94)	0.043
		Officer	0.8	3.2	0.25 (0.07,0.86)	0.033
		Enlisted Flyer	0.6	3.5	0.17 (0.02,1.41)	0.137
		Enlisted Ground.	1.9	1.7	1.10 (0.43,2.82)	0.999
11-25	Achilles Reflex	All	10.0	9.1	1.11 (0.83,1.48)	0.519
		Officer	12.1	9.4	1.32 (0.85,2.04)	0.257
		Enlisted Flyer	9.9	10.6	0.93 (0.47,1.85)	0.971
		Enlisted Ground.	8.2	8.2	0.99 (0.63,1.57)	0.999
11-26	Biceps Reflex	All	0.7	1.1	0.67 (0.27,1.67)	0.524
		Officer	1.4	1.2	1.14 (0.35,3.76)	0.999
		Enlisted Flyer	0.0	1.0	--	0.580
		Enlisted Ground.	0.5	1.0	0.46 (0.09,2.27)	0.532
11-27	Babinski Reflex	All	0.3	0.6	0.50 (0.13,1.91)	0.469
		Officer	0.0	0.6	--	0.367
		Enlisted Flyer	0.0	1.0	--	0.578
		Enlisted Ground.	0.7	0.5	1.38 (0.28,6.86)	0.999
11-30	Tremor	All	3.0	2.7	1.12 (0.67,1.85)	0.771
		Officer	2.2	4.0	0.54 (0.23,1.23)	0.194
		Enlisted Flyer	3.7	1.0	3.87 (0.77,19.41)	0.161
		Enlisted Ground.	3.3	2.1	1.63 (0.74,3.55)	0.304
11-31	Coordination	All	2.2	2.0	1.14 (0.63,2.04)	0.781
		Officer	2.2	2.2	1.00 (0.40,2.50)	0.999
		Enlisted Flyer	1.2	2.5	0.49 (0.09,2.56)	0.632
		Enlisted Ground.	2.6	1.6	1.70 (0.70,4.14)	0.342
11-32	Romberg Sign	All	0.5	0.5	1.13 (0.34,3.70)	0.999
		Officer	0.5	0.4	1.37 (0.19,9.76)	0.999
		Enlisted Flyer	0.0	1.5	--	0.332
		Enlisted Ground.	0.7	0.2	4.15 (0.43,40.01)	0.408

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
11-33	Gait	All	3.5	3.1	1.12 (0.70,1.79)	0.732
		Officer	2.7	3.0	0.91 (0.40,2.04)	0.973
		Enlisted Flyer	3.7	4.4	0.83 (0.29,2.38)	0.933
		Enlisted Ground.	4.1	2.8	1.48 (0.74,2.97)	0.351
11-34	Central Nervous System (CNS) Index	All	6.0	5.9	1.03 (0.72,1.47)	0.950
		Officer	4.9	6.2	0.78 (0.43,1.43)	0.515
		Enlisted Flyer	6.8	6.4	1.06 (0.46,2.43)	0.999
		Enlisted Ground.	6.7	5.4	1.26 (0.74,2.13)	0.470
12-3	Psychoses	All	2.9	2.9	0.98 (0.60,1.63)	0.999
		Officer	1.9	2.0	0.96 (0.36,2.53)	0.999
		Enlisted Flyer	4.3	2.0	2.25 (0.65,7.81)	0.319
		Enlisted Ground.	3.1	4.0	0.77 (0.38,1.53)	0.563
12-4	Alcohol Dependence	All	7.5	6.6	1.15 (0.83,1.60)	0.451
		Officer	4.6	5.2	0.89 (0.47,1.66)	0.829
		Enlisted Flyer	9.9	8.4	1.20 (0.59,2.45)	0.754
		Enlisted Ground.	9.1	7.1	1.30 (0.82,2.05)	0.324
12-5	Drug Dependence	All	0.1	0.3	0.34 (0.04,3.02)	0.569
		Officer	0.0	0.2	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.5	0.46 (0.05,4.40)	0.850
12-6	Anxiety	All	14.8	14.1	1.06 (0.84,1.35)	0.670
		Officer	6.8	6.4	1.08 (0.63,1.85)	0.903
		Enlisted Flyer	16.8	16.8	1.00 (0.58,1.74)	0.999
		Enlisted Ground.	21.1	19.9	1.08 (0.79,1.47)	0.700
12-7	Other Neuroses	All	40.3	36.8	1.16 (0.98,1.38)	0.101
		Officer	28.6	29.5	0.96 (0.71,1.29)	0.836
		Enlisted Flyer	48.1	43.5	1.21 (0.79,1.83)	0.442
		Enlisted Ground.	47.6	40.8	1.32 (1.02,1.70)	0.040
12-8	SCL-90-R Anxiety	All	7.8	5.8	1.38 (0.99,1.93)	0.071
		Officer	3.5	2.4	1.50 (0.68,3.32)	0.428
		Enlisted Flyer	11.2	6.9	1.70 (0.82,3.53)	0.212
		Enlisted Ground.	10.2	8.4	1.25 (0.81,1.93)	0.363
12-9	SCL-90-R Depression	All	10.1	8.8	1.16 (0.87,1.55)	0.337
		Officer	6.5	5.2	1.28 (0.72,2.27)	0.487
		Enlisted Flyer	14.9	11.3	1.37 (0.74,2.53)	0.393
		Enlisted Ground.	11.4	11.1	1.03 (0.69,1.53)	0.964

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
12-10	SCL-90-R Hostility	All	6.1	4.1	1.51 (1.03,2.21)	0.044
		Officer	1.6	2.4	0.68 (0.25,1.82)	0.592
		Enlisted Flyer	9.9	4.9	2.13 (0.94,4.83)	0.101
		Enlisted Ground.	8.6	5.4	1.65 (1.00,2.71)	0.064
12-11	SCL-90-R Interpersonal Sensitivity	All	10.4	9.2	1.16 (0.87,1.54)	0.343
		Officer	4.4	4.8	0.91 (0.47,1.73)	0.892
		Enlisted Flyer	13.7	10.3	1.37 (0.73,2.60)	0.417
		Enlisted Ground.	14.5	12.5	1.19 (0.82,1.71)	0.411
12-12	SCL-90-R Obsessive-Compulsive Behavior	All	11.0	8.7	1.30 (0.98,1.72)	0.082
		Officer	6.3	5.2	1.22 (0.69,2.18)	0.596
		Enlisted Flyer	14.9	11.3	1.37 (0.74,2.53)	0.393
		Enlisted Ground.	13.6	10.8	1.30 (0.89,1.91)	0.215
12-13	SCL-90-R Paranoid Ideation	All	7.0	4.6	1.55 (1.08,2.22)	0.022
		Officer	3.0	2.4	1.26 (0.55,2.89)	0.740
		Enlisted Flyer	9.3	5.4	1.79 (0.80,4.02)	0.219
		Enlisted Ground.	9.5	6.3	1.58 (0.99,2.52)	0.073
12-14	SCL-90-R Phobic Anxiety	All	8.4	8.0	1.06 (0.78,1.44)	0.751
		Officer	2.5	2.8	0.88 (0.37,2.04)	0.923
		Enlisted Flyer	10.6	8.9	1.21 (0.60,2.44)	0.715
		Enlisted Ground.	12.9	12.2	1.06 (0.73,1.56)	0.822
12-15	SCL-90-R Psychoticism	All	9.6	8.8	1.10 (0.82,1.46)	0.587
		Officer	5.2	4.8	1.09 (0.59,2.01)	0.920
		Enlisted Flyer	11.8	8.9	1.38 (0.70,2.72)	0.456
		Enlisted Ground.	12.6	12.4	1.03 (0.70,1.50)	0.975
12-16	SCL-90-R Somatization	All	10.2	7.7	1.36 (1.01,1.82)	0.048
		Officer	5.2	3.6	1.47 (0.76,2.83)	0.331
		Enlisted Flyer	12.4	9.9	1.30 (0.67,2.51)	0.542
		Enlisted Ground.	13.8	10.6	1.35 (0.92,1.98)	0.150
12-17	SCL-90-R Global Severity Index	All	9.8	7.7	1.30 (0.96,1.74)	0.100
		Officer	4.6	4.0	1.17 (0.60,2.26)	0.771
		Enlisted Flyer	13.0	8.9	1.54 (0.79,3.00)	0.267
		Enlisted Ground.	13.1	10.6	1.27 (0.86,1.87)	0.268
12-18	SCL-90-R Positive Symptom Total	All	11.0	9.6	1.16 (0.88,1.53)	0.331
		Officer	5.5	5.6	0.97 (0.54,1.76)	0.929
		Enlisted Flyer	13.7	10.3	1.37 (0.73,2.60)	0.330
		Enlisted Ground.	14.8	12.9	1.17 (0.82,1.69)	0.392

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
12-19	SCL-90-R Positive Symptom Distress Index	All	7.8	7.5	1.04 (0.76,1.43)	0.855
		Officer	4.6	4.2	1.11 (0.58,2.14)	0.884
		Enlisted Flyer	9.9	10.8	0.91 (0.46,1.79)	0.915
		Enlisted Ground.	9.8	9.2	1.07 (0.69,1.64)	0.857
13-3	Hepatitis (Non-A, Non-B, and Non-C)	All	1.7	1.7	1.03 (0.53,1.98)	0.999
		Officer	1.1	1.0	1.09 (0.29,4.10)	0.999
		Enlisted Flyer	3.1	1.5	2.12 (0.50,9.02)	0.495
		Enlisted Ground.	1.7	2.3	0.73 (0.29,1.85)	0.668
13-4	Jaundice	All	1.8	3.0	0.61 (0.34,1.09)	0.123
		Officer	2.5	4.1	0.61 (0.27,1.35)	0.294
		Enlisted Flyer	2.5	1.0	2.49 (0.45,13.76)	0.506
		Enlisted Ground.	1.0	2.7	0.36 (0.12,1.09)	0.099
13-5	Acute and Subacute Necrosis of the Liver	All	0.0	0.1	--	--
		Officer	0.0	0.2	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.0	--	--
13-6	Alcoholic Chronic Liver Disease and Cirrhosis	All	5.4	5.4	1.00 (0.68,1.47)	0.999
		Officer	5.7	3.8	1.53 (0.80,2.93)	0.265
		Enlisted Flyer	6.1	6.3	0.97 (0.40,2.37)	0.999
		Enlisted Ground.	4.9	6.5	0.74 (0.42,1.32)	0.378
13-7	Nonalcoholic Chronic Liver Disease and Cirrhosis	All	1.4	1.0	1.35 (0.62,2.92)	0.574
		Officer	1.4	0.6	2.29 (0.54,9.66)	0.422
		Enlisted Flyer	1.2	1.0	1.26 (0.18,9.02)	0.999
		Enlisted Ground.	1.4	1.4	1.02 (0.35,2.97)	0.999
13-8	Liver Abscess and Sequelae of Chronic Liver Disease	All	0.1	0.1	--	--
		Officer	0.0	0.2	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.0	--	--
13-9	Other Liver Disorders	All	30.1	27.9	1.11 (0.92,1.34)	0.281
		Officer	29.4	27.1	1.12 (0.83,1.51)	0.513
		Enlisted Flyer	25.3	27.1	0.91 (0.57,1.46)	0.791
		Enlisted Ground.	32.5	28.8	1.19 (0.91,1.56)	0.240
13-10	Hepatomegaly	All	1.7	2.7	0.63 (0.34,1.14)	0.163
		Officer	1.4	2.4	0.56 (0.20,1.61)	0.400
		Enlisted Flyer	3.7	1.5	2.56 (0.63,10.42)	0.306
		Enlisted Ground.	1.2	3.3	0.35 (0.13,0.95)	0.052

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
13-11	Current Hepatomegaly	All	0.6	0.8	0.80 (0.29,2.20)	0.854
		Officer	0.5	0.8	0.68 (0.12,3.72)	0.972
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.7	1.1	0.67 (0.17,2.70)	0.822
13-13	AST	All	2.7	3.5	0.75 (0.46,1.24)	0.316
		Officer	3.6	4.0	0.89 (0.44,1.81)	0.881
		Enlisted Flyer	1.2	3.6	0.34 (0.07,1.65)	0.286
		Enlisted Ground.	2.4	3.0	0.79 (0.36,1.74)	0.698
13-15	ALT	All	5.5	7.2	0.76 (0.53,1.08)	0.144
		Officer	5.8	6.1	0.96 (0.54,1.70)	0.998
		Enlisted Flyer	4.3	6.6	0.64 (0.25,1.63)	0.474
		Enlisted Ground.	5.8	8.4	0.67 (0.40,1.12)	0.155
13-17	GGT	All	19.9	18.4	1.10 (0.89,1.36)	0.414
		Officer	19.4	16.8	1.19 (0.84,1.70)	0.369
		Enlisted Flyer	17.9	20.9	0.82 (0.49,1.40)	0.560
		Enlisted Ground.	21.2	19.0	1.14 (0.83,1.56)	0.461
13-19	Alkaline Phosphatase	All	5.2	3.4	1.59 (1.04,2.42)	0.039
		Officer	2.8	2.6	1.06 (0.46,2.44)	0.999
		Enlisted Flyer	4.3	4.6	0.94 (0.34,2.58)	0.999
		Enlisted Ground.	7.7	3.6	2.26 (1.27,4.01)	0.007
13-21	Total Bilirubin	All	5.1	4.8	1.07 (0.73,1.58)	0.805
		Officer	5.8	5.3	1.11 (0.62,2.01)	0.837
		Enlisted Flyer	3.1	4.1	0.75 (0.24,2.33)	0.828
		Enlisted Ground.	5.3	4.6	1.15 (0.64,2.06)	0.746
13-22	Direct Bilirubin	All	1.4	2.4	0.57 (0.30,1.10)	0.127
		Officer	2.5	2.2	1.13 (0.46,2.74)	0.976
		Enlisted Flyer	0.6	1.0	0.61 (0.05,6.75)	0.999
		Enlisted Ground.	0.7	3.0	0.23 (0.07,0.80)	0.022
13-24	LDH	All	14.4	14.2	1.01 (0.80,1.29)	0.957
		Officer	13.1	13.3	0.98 (0.65,1.46)	0.987
		Enlisted Flyer	14.8	15.3	0.96 (0.54,1.72)	0.999
		Enlisted Ground.	15.4	14.6	1.06 (0.74,1.51)	0.809
13-26	Cholesterol	All	15.0	13.5	1.13 (0.89,1.44)	0.340
		Officer	12.2	10.9	1.13 (0.74,1.73)	0.637
		Enlisted Flyer	19.8	14.3	1.48 (0.85,2.58)	0.216
		Enlisted Ground.	15.6	15.5	1.01 (0.71,1.43)	0.999

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
13-28	HDL Cholesterol	All	10.9	8.5	1.33 (0.99,1.77)	0.064
		Officer	11.3	7.5	1.57 (0.98,2.51)	0.077
		Enlisted Flyer	8.9	10.9	0.80 (0.39,1.62)	0.653
		Enlisted Ground.	11.4	8.4	1.39 (0.91,2.13)	0.159
13-30	Cholesterol-HDL Ratio	All	59.0	56.6	1.10 (0.93,1.31)	0.287
		Officer	51.0	49.1	1.08 (0.82,1.42)	0.633
		Enlisted Flyer	63.9	64.8	0.96 (0.62,1.50)	0.959
		Enlisted Ground.	64.0	60.5	1.16 (0.89,1.51)	0.295
13-32	Triglycerides	All	11.2	9.3	1.22 (0.93,1.61)	0.179
		Officer	11.9	7.9	1.58 (1.00,2.50)	0.063
		Enlisted Flyer	13.6	11.2	1.24 (0.66,2.34)	0.607
		Enlisted Ground.	9.6	10.0	0.96 (0.63,1.47)	0.942
13-34	Creatine Kinase	All	14.1	13.8	1.02 (0.80,1.30)	0.916
		Officer	13.9	11.7	1.21 (0.81,1.82)	0.410
		Enlisted Flyer	11.1	14.8	0.72 (0.38,1.35)	0.384
		Enlisted Ground.	15.4	15.3	1.01 (0.71,1.43)	0.999
13-36	Serum Amylase	All	6.4	7.0	0.90 (0.64,1.27)	0.618
		Officer	6.9	9.1	0.74 (0.45,1.24)	0.310
		Enlisted Flyer	3.1	3.1	1.01 (0.30,3.37)	0.999
		Enlisted Ground.	7.2	6.6	1.10 (0.67,1.82)	0.798
13-37	Antibodies for Hepatitis A	All	33.5	34.0	0.98 (0.82,1.17)	0.849
		Officer	25.9	25.1	1.04 (0.77,1.42)	0.854
		Enlisted Flyer	47.5	44.6	1.13 (0.74,1.71)	0.645
		Enlisted Ground.	34.8	38.0	0.87 (0.67,1.13)	0.321
13-38	Serological Evidence of Present or Prior Hepatitis B Infection	All	10.7	15.5	0.66 (0.51,0.85)	0.001
		Officer	5.2	9.4	0.53 (0.30,0.92)	0.030
		Enlisted Flyer	13.6	21.3	0.58 (0.33,1.02)	0.077
		Enlisted Ground.	14.4	18.8	0.73 (0.52,1.03)	0.086
13-39	Antibodies for Hepatitis C	All	0.8	1.8	0.46 (0.21,1.04)	0.084
		Officer	0.8	1.4	0.58 (0.15,2.27)	0.641
		Enlisted Flyer	0.0	2.0	--	--
		Enlisted Ground.	1.2	2.1	0.56 (0.20,1.61)	0.400
13-40	Stool Hemocult	All	2.6	1.9	1.35 (0.75,2.41)	0.397
		Officer	2.6	1.7	1.54 (0.59,4.04)	0.522
		Enlisted Flyer	0.0	1.0	--	--
		Enlisted Ground.	3.6	2.5	1.47 (0.68,3.15)	0.433

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
13-42	Prealbumin	All	1.3	1.3	1.00 (0.47,2.13)	0.999
		Officer	1.1	2.0	0.54 (0.17,1.75)	0.444
		Enlisted Flyer	1.2	1.0	1.21 (0.17,8.70)	0.999
		Enlisted Ground.	1.4	0.7	2.04 (0.57,7.28)	0.423
13-44	Albumin	All	2.4	2.2	1.10 (0.63,1.92)	0.852
		Officer	2.2	1.4	1.58 (0.57,4.40)	0.536
		Enlisted Flyer	1.9	3.6	0.51 (0.13,2.00)	0.509
		Enlisted Ground.	2.9	2.5	1.16 (0.53,2.54)	0.859
13-46	α -1 Acid Glycoprotein	All	2.2	2.7	0.82 (0.47,1.42)	0.570
		Officer	1.4	2.6	0.52 (0.18,1.47)	0.313
		Enlisted Flyer	3.7	3.6	1.04 (0.34,3.15)	0.999
		Enlisted Ground.	2.4	2.5	0.96 (0.42,2.19)	0.999
13-50	α -2 Macroglobulin	All	0.4	0.5	0.89 (0.25,3.16)	0.999
		Officer	0.0	0.4	--	--
		Enlisted Flyer	0.6	1.0	0.60 (0.05,6.71)	0.999
		Enlisted Ground.	0.7	0.4	2.03 (0.34,12.23)	0.735
13-52	Apolipoprotein B	All	73.9	72.1	1.09 (0.90,1.32)	0.384
		Officer	70.4	69.1	1.06 (0.79,1.43)	0.746
		Enlisted Flyer	79.6	82.1	0.85 (0.50,1.44)	0.640
		Enlisted Ground.	74.8	71.4	1.19 (0.89,1.58)	0.266
13-54	C ₃ Complement	All	2.6	2.4	1.07 (0.62,1.84)	0.918
		Officer	2.8	3.2	0.85 (0.38,1.90)	0.851
		Enlisted Flyer	2.5	3.6	0.68 (0.20,2.38)	0.769
		Enlisted Ground.	2.4	1.2	1.95 (0.74,5.17)	0.261
13-56	C ₄ Complement	All	0.6	0.7	0.89 (0.32,2.51)	0.999
		Officer	0.8	0.6	1.37 (0.28,6.85)	0.999
		Enlisted Flyer	0.6	2.6	0.24 (0.03,2.05)	0.315
		Enlisted Ground.	0.5	0.2	2.71 (0.24,29.99)	0.793
13-58	Haptoglobin	All	13.5	11.2	1.24 (0.96,1.61)	0.110
		Officer	9.7	9.1	1.07 (0.67,1.71)	0.856
		Enlisted Flyer	18.5	15.8	1.21 (0.70,2.10)	0.592
		Enlisted Ground.	14.9	11.4	1.36 (0.94,1.98)	0.127
13-60	Transferrin	All	11.9	14.1	0.82 (0.64,1.06)	0.149
		Officer	12.2	15.2	0.78 (0.52,1.16)	0.255
		Enlisted Flyer	16.7	13.8	1.25 (0.70,2.23)	0.540
		Enlisted Ground.	9.9	13.3	0.71 (0.47,1.06)	0.117

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
14-3	Occurrence of Acne (Lifetime)	All	87.2	84.9	1.21 (0.95,1.55)	0.134
		Officer	88.0	85.9	1.21 (0.81,1.81)	0.410
		Enlisted Flyer	85.2	88.2	0.77 (0.42,1.42)	0.494
		Enlisted Ground.	87.2	82.8	1.42 (0.99,2.03)	0.067
14-4	Acne Relative to Time of Duty in SEA (Pre- and Post-SEA and Post-SEA vs. Pre-SEA and None)	All	86.8	84.5	1.20 (0.94,1.53)	0.158
		Officer	87.5	85.7	1.17 (0.79,1.74)	0.504
		Enlisted Flyer	84.0	88.2	0.70 (0.39,1.28)	0.311
		Enlisted Ground.	87.2	82.3	1.47 (1.03,2.10)	0.042
14-5	Acne Relative to Time of Duty in SEA (Post-SEA vs. None)	All	85.8	83.1	1.23 (0.96,1.57)	0.116
		Officer	86.9	84.2	1.24 (0.83,1.86)	0.350
		Enlisted Flyer	83.4	87.1	0.75 (0.41,1.38)	0.437
		Enlisted Ground.	85.8	80.7	1.44 (1.00,2.07)	0.059
14-6	Acne Relative to Time of Duty in SEA (Pre- and Post-SEA vs. Pre-SEA)	All	95.7	97.0	0.70 (0.17,2.85)	0.888
		Officer	93.8	98.1	0.29 (0.03,3.38)	0.665
		Enlisted Flyer	88.2	100.0	0.18 (0.01,3.98)	0.466
		Enlisted Ground.	100.0	95.2	5.15 (0.26,102.22)	0.383
14-8	Location of Acne (Post-SEA)	All	46.1	44.1	1.08 (0.89,1.32)	0.443
		Officer	48.1	46.7	1.06 (0.78,1.44)	0.777
		Enlisted Flyer	43.8	48.8	0.82 (0.51,1.31)	0.479
		Enlisted Ground.	45.2	40.0	1.24 (0.92,1.67)	0.175
14-10	Location of Acne (Pre- and Post-SEA and Post-SEA)	All	46.6	45.7	1.04 (0.87,1.25)	0.716
		Officer	47.4	49.1	0.93 (0.70,1.25)	0.695
		Enlisted Flyer	44.9	46.9	0.92 (0.59,1.44)	0.801
		Enlisted Ground.	46.6	42.1	1.20 (0.91,1.58)	0.215
14-11	Other Abnormalities	All	83.6	81.9	1.13 (0.90,1.41)	0.329
		Officer	85.8	83.6	1.19 (0.81,1.73)	0.429
		Enlisted Flyer	84.6	86.6	0.85 (0.47,1.52)	0.683
		Enlisted Ground.	81.3	78.8	1.17 (0.85,1.61)	0.370
14-12	Dermatology Index	All	43.8	45.3	0.94 (0.80,1.11)	0.505
		Officer	38.1	39.8	0.93 (0.71,1.23)	0.664
		Enlisted Flyer	44.4	53.5	0.70 (0.46,1.06)	0.108
		Enlisted Ground.	48.5	47.2	1.05 (0.82,1.35)	0.746
15-3	Verified Essential Hypertension	All	38.6	38.3	1.01 (0.85,1.21)	0.922
		Officer	37.5	39.8	0.91 (0.69,1.20)	0.547
		Enlisted Flyer	44.4	38.9	1.25 (0.82,1.91)	0.347
		Enlisted Ground.	37.3	36.8	1.02 (0.79,1.33)	0.922

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
15-4	Verified Heart Disease (Excluding Hypertension)	All	49.8	48.2	1.07 (0.90,1.26)	0.481
		Officer	54.0	54.3	0.99 (0.75,1.30)	0.997
		Enlisted Flyer	55.0	45.5	1.46 (0.96,2.22)	0.093
		Enlisted Ground.	44.2	43.8	1.01 (0.79,1.31)	0.973
15-5	Verified Myocardial Infarction	All	6.9	6.7	1.03 (0.74,1.44)	0.936
		Officer	5.8	6.7	0.86 (0.49,1.51)	0.700
		Enlisted Flyer	10.0	8.4	1.21 (0.59,2.48)	0.737
		Enlisted Ground.	6.7	6.2	1.09 (0.65,1.82)	0.842
15-7	Systolic Blood Pressure	All	15.2	15.6	0.97 (0.77,1.23)	0.853
		Officer	16.6	18.1	0.90 (0.63,1.29)	0.641
		Enlisted Flyer	17.0	14.9	1.17 (0.67,2.07)	0.685
		Enlisted Ground.	13.4	13.7	0.97 (0.67,1.40)	0.942
15-8	Heart Sounds	All	20.5	20.2	1.02 (0.83,1.26)	0.888
		Officer	23.6	22.0	1.10 (0.80,1.52)	0.625
		Enlisted Flyer	20.3	16.3	1.30 (0.76,2.23)	0.412
		Enlisted Ground.	17.9	20.0	0.88 (0.63,1.21)	0.466
15-9	Overall Electrocardiograph (ECG)	All	20.7	23.4	0.86 (0.70,1.05)	0.151
		Officer	22.7	26.5	0.82 (0.59,1.12)	0.240
		Enlisted Flyer	26.3	25.2	1.05 (0.66,1.69)	0.924
		Enlisted Ground.	16.9	20.1	0.81 (0.58,1.13)	0.240
15-10	ECG: Right Bundle Branch Block (RBBB)	All	1.3	1.5	0.85 (0.41,1.75)	0.785
		Officer	0.6	1.4	0.39 (0.08,1.87)	0.373
		Enlisted Flyer	3.1	1.0	3.21 (0.61,16.77)	0.283
		Enlisted Ground.	1.2	1.8	0.67 (0.23,1.99)	0.648
15-11	ECG: Left Bundle Branch Block (LBBB)	All	0.1	0.8	--	--
		Officer	0.3	1.4	--	--
		Enlisted Flyer	0.0	0.5	--	--
		Enlisted Ground.	0.0	0.4	--	--
15-12	ECG: Nonspecific ST- and T-Wave Changes	All	14.0	14.6	0.96 (0.75,1.22)	0.757
		Officer	15.0	14.7	1.02 (0.70,1.50)	0.982
		Enlisted Flyer	20.6	17.9	1.19 (0.70,2.02)	0.605
		Enlisted Ground.	10.7	13.4	0.78 (0.53,1.15)	0.249
15-13	ECG: Bradycardia	All	3.2	2.3	1.40 (0.84,2.35)	0.250
		Officer	3.6	3.7	0.98 (0.48,2.04)	0.999
		Enlisted Flyer	4.4	0.5	9.20 (1.12,75.54)	0.033
		Enlisted Ground.	2.4	1.8	1.36 (0.56,3.31)	0.644

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
15-14	ECG: Tachycardia	All	0.3	0.2	--	--
		Officer	0.6	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.2	0.4	--	--
15-15	ECG: Arrhythmia	All	4.7	4.5	1.04 (0.69,1.55)	0.940
		Officer	5.0	5.3	0.94 (0.51,1.74)	0.964
		Enlisted Flyer	4.4	5.4	0.79 (0.30,2.10)	0.824
		Enlisted Ground.	4.5	3.5	1.30 (0.69,2.47)	0.521
15-16	ECG: Evidence of Prior Myocardial Infarction	All	3.4	3.4	1.00 (0.63,1.59)	0.999
		Officer	3.6	4.3	0.84 (0.41,1.69)	0.745
		Enlisted Flyer	4.4	4.0	1.11 (0.39,3.13)	0.999
		Enlisted Ground.	2.9	2.5	1.17 (0.53,2.55)	0.851
15-17	ECG: Other Diagnoses	All	1.1	0.4	2.70 (0.92,7.94)	0.105
		Officer	0.8	0.4	2.05 (0.34,12.35)	0.727
		Enlisted Flyer	1.3	0.5	2.54 (0.23,28.31)	0.839
		Enlisted Ground.	1.2	0.4	3.42 (0.66,17.70)	0.241
15-19	Diastolic Blood Pressure	All	2.8	3.2	0.85 (0.52,1.40)	0.601
		Officer	3.1	3.0	1.00 (0.46,2.21)	0.999
		Enlisted Flyer	3.8	2.5	1.54 (0.46,5.12)	0.694
		Enlisted Ground.	2.1	3.7	0.57 (0.26,1.26)	0.225
15-20	Funduscopy Examination	All	7.3	5.5	1.35 (0.96,1.91)	0.103
		Officer	6.1	4.3	1.46 (0.79,2.70)	0.289
		Enlisted Flyer	11.3	5.5	2.19 (1.00,4.79)	0.069
		Enlisted Ground.	6.7	6.5	1.03 (0.62,1.72)	0.999
15-21	Carotid Bruits	All	1.8	1.3	1.43 (0.72,2.85)	0.394
		Officer	1.4	1.8	0.75 (0.25,2.27)	0.817
		Enlisted Flyer	2.5	1.0	2.56 (0.46,14.18)	0.482
		Enlisted Ground.	1.9	0.9	2.19 (0.71,6.74)	0.264
15-22	Radial Pulses	All	0.4	0.4	1.07 (0.29,4.01)	0.999
		Officer	0.6	0.2	2.74 (0.25,30.28)	0.787
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.5	0.7	0.68 (0.12,3.71)	0.969
15-23	Femoral Pulses	All	1.2	0.6	2.12 (0.82,5.50)	0.178
		Officer	1.1	0.4	2.75 (0.50,15.07)	0.426
		Enlisted Flyer	1.3	1.5	0.84 (0.14,5.09)	0.999
		Enlisted Ground.	1.2	0.4	3.42 (0.66,17.70)	0.241

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
15-24	Popliteal Pulses	All	2.0	0.9	2.34 (1.11,4.95)	0.035
		Officer	1.9	0.8	2.41 (0.70,8.29)	0.259
		Enlisted Flyer	2.5	1.5	1.69 (0.37,7.67)	0.760
		Enlisted Ground.	1.9	0.7	2.75 (0.82,9.18)	0.157
15-25	Dorsalis Pedis Pulses	All	8.6	7.0	1.26 (0.92,1.72)	0.175
		Officer	8.1	6.7	1.22 (0.72,2.04)	0.544
		Enlisted Flyer	8.1	9.5	0.85 (0.41,1.77)	0.799
		Enlisted Ground.	9.3	6.3	1.52 (0.95,2.44)	0.103
15-26	Posterior Tibial Pulses	All	3.8	2.3	1.69 (1.03,2.78)	0.049
		Officer	3.0	2.4	1.26 (0.55,2.88)	0.747
		Enlisted Flyer	5.0	3.0	1.71 (0.58,5.04)	0.477
		Enlisted Ground.	4.1	1.9	2.14 (0.99,4.62)	0.074
15-27	Leg Pulses	All	9.6	7.7	1.27 (0.94,1.72)	0.132
		Officer	8.3	6.9	1.22 (0.73,2.04)	0.523
		Enlisted Flyer	9.4	10.4	0.89 (0.44,1.79)	0.884
		Enlisted Ground.	10.8	7.4	1.51 (0.97,2.35)	0.083
15-28	Peripheral Pulses	All	9.7	8.1	1.22 (0.91,1.64)	0.213
		Officer	8.6	7.1	1.23 (0.74,2.03)	0.503
		Enlisted Flyer	9.4	10.4	0.89 (0.44,1.79)	0.884
		Enlisted Ground.	10.8	8.1	1.37 (0.89,2.11)	0.187
15-29	Kidney, Urethra, and Bladder (KUB) X Ray (Excluding Kidney Stones)	All	30.6	31.0	0.98 (0.82,1.18)	0.873
		Officer	33.8	31.3	1.12 (0.84,1.50)	0.487
		Enlisted Flyer	35.2	31.7	1.17 (0.76,1.82)	0.551
		Enlisted Ground.	26.1	30.5	0.80 (0.61,1.07)	0.147
15-30	Intermittent Claudication and Vascular Insufficiency (ICVI) Index	All	3.7	2.1	1.77 (1.06,2.94)	0.037
		Officer	3.9	2.0	1.94 (0.85,4.42)	0.163
		Enlisted Flyer	5.0	2.5	2.07 (0.67,6.47)	0.318
		Enlisted Ground.	3.1	2.1	1.48 (0.67,3.27)	0.445
16-10	Hematocrit	All	1.7	1.3	1.36 (0.68,2.73)	0.496
		Officer	1.7	2.2	0.75 (0.27,2.04)	0.746
		Enlisted Flyer	2.5	0.5	5.06 (0.56,45.75)	0.250
		Enlisted Ground.	1.4	0.7	2.07 (0.58,7.39)	0.409
16-12	Platelet Count	All	1.4	0.9	1.47 (0.67,3.23)	0.449
		Officer	0.3	0.6	0.46 (0.05,4.41)	0.851
		Enlisted Flyer	1.2	1.0	1.24 (0.17,8.93)	0.999
		Enlisted Ground.	2.4	1.2	1.98 (0.75,5.25)	0.248

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
16-14	Prothrombin Time	All	0.9	0.6	1.55 (0.56,4.30)	0.555
		Officer	1.2	0.9	1.36 (0.34,5.50)	0.937
		Enlisted Flyer	1.4	1.1	1.26 (0.18,9.05)	0.999
		Enlisted Ground.	0.5	0.2	2.78 (0.25,30.74)	0.777
16-15	RBC Morphology	All	44.6	46.2	0.94 (0.79,1.11)	0.493
		Officer	47.3	47.3	1.00 (0.76,1.31)	0.999
		Enlisted Flyer	50.6	47.8	1.12 (0.74,1.70)	0.663
		Enlisted Ground.	40.0	44.6	0.83 (0.64,1.07)	0.164
16-17	Absolute Neutrophils (bands) (Zero vs. Nonzero)	All	16.9	16.6	1.02 (0.82,1.28)	0.884
		Officer	16.2	14.8	1.12 (0.77,1.62)	0.629
		Enlisted Flyer	15.4	18.4	0.81 (0.46,1.41)	0.543
		Enlisted Ground.	18.1	17.5	1.04 (0.75,1.44)	0.885
16-20	Absolute Eosinophils (Zero vs. Nonzero)	All	10.0	12.8	0.76 (0.58,0.99)	0.050
		Officer	9.3	15.0	0.59 (0.38,0.90)	0.018
		Enlisted Flyer	8.0	11.9	0.64 (0.32,1.31)	0.293
		Enlisted Ground.	11.4	11.3	1.01 (0.68,1.51)	0.999
16-21	Absolute Basophils (Zero vs. Nonzero)	All	45.0	45.3	0.99 (0.84,1.17)	0.932
		Officer	44.0	45.3	0.95 (0.72,1.24)	0.744
		Enlisted Flyer	43.2	45.3	0.92 (0.61,1.40)	0.774
		Enlisted Ground.	46.7	45.3	1.06 (0.82,1.36)	0.719
17-3	Kidney Disease	All	17.0	15.9	1.08 (0.86,1.36)	0.545
		Officer	17.3	14.0	1.28 (0.88,1.87)	0.225
		Enlisted Flyer	16.5	15.0	1.12 (0.63,1.98)	0.818
		Enlisted Ground.	16.9	17.8	0.93 (0.67,1.31)	0.754
17-4	Kidney Stones	All	3.0	2.7	1.12 (0.68,1.84)	0.755
		Officer	3.3	3.6	0.91 (0.43,1.91)	0.949
		Enlisted Flyer	3.7	3.0	1.26 (0.40,3.99)	0.918
		Enlisted Ground.	2.6	1.9	1.37 (0.59,3.19)	0.605
17-5	Urinary Protein	All	4.6	4.5	1.02 (0.68,1.53)	0.995
		Officer	4.6	2.8	1.69 (0.82,3.48)	0.207
		Enlisted Flyer	3.7	5.4	0.67 (0.24,1.86)	0.603
		Enlisted Ground.	5.0	5.7	0.86 (0.49,1.51)	0.701
17-6	Urinary Red Blood Cell Count	All	3.3	2.3	1.40 (0.84,2.34)	0.237
		Officer	2.5	1.2	2.08 (0.73,5.89)	0.254
		Enlisted Flyer	2.5	2.0	1.26 (0.31,5.12)	0.999
		Enlisted Ground.	4.3	3.5	1.24 (0.65,2.37)	0.636

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
17-7	Urinary White Blood Cell Count	All	3.5	2.5	1.40 (0.86,2.30)	0.222
		Officer	1.9	2.0	0.96 (0.36,2.54)	0.999
		Enlisted Flyer	4.3	5.0	0.87 (0.32,2.35)	0.984
		Enlisted Ground.	4.5	2.1	2.21 (1.06,4.61)	0.047
18-3	Past Thyroid Disease	All	5.3	5.6	0.93 (0.64,1.35)	0.787
		Officer	6.3	5.8	1.09 (0.62,1.92)	0.869
		Enlisted Flyer	5.0	3.4	1.46 (0.52,4.13)	0.646
		Enlisted Ground.	4.5	6.3	0.71 (0.40,1.25)	0.291
18-4	Composite Diabetes Indicator	All	15.0	14.0	1.08 (0.85,1.37)	0.576
		Officer	15.1	11.6	1.36 (0.91,2.02)	0.157
		Enlisted Flyer	15.4	17.8	0.84 (0.48,1.47)	0.642
		Enlisted Ground.	14.7	14.9	0.99 (0.69,1.41)	0.999
18-7	Thyroid Gland	All	0.5	0.8	0.67 (0.23,1.95)	0.628
		Officer	0.6	0.6	0.90 (0.15,5.41)	0.999
		Enlisted Flyer	0.0	1.0	--	--
		Enlisted Ground.	0.7	0.9	0.81 (0.19,3.40)	0.999
18-10	Retinopathy Results (Diabetics)	All	5.0	2.8	1.81 (0.56,5.82)	0.479
		Officer	3.7	3.5	1.06 (0.14,7.79)	0.999
		Enlisted Flyer	12.0	0.0	--	--
		Enlisted Ground.	3.2	3.5	0.91 (0.15,5.62)	0.999
18-11	Neuropathy Results (Diabetics)	All	12.0	6.7	1.89 (0.87,4.11)	0.150
		Officer	9.1	5.2	1.83 (0.42,8.07)	0.656
		Enlisted Flyer	12.0	13.9	0.85 (0.18,3.91)	0.999
		Enlisted Ground.	14.5	4.7	3.44 (1.01,11.74)	0.076
18-12	Radial Pulses (Doppler) (Diabetics)	All	1.4	0.6	2.54 (0.23,28.33)	0.840
		Officer	1.8	1.7	1.06 (0.06,17.30)	0.999
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	1.6	0.0	--	--
18-13	Femoral Pulses (Doppler) (Diabetics)	All	4.2	2.2	1.93 (0.53,6.98)	0.486
		Officer	7.3	0.0	--	--
		Enlisted Flyer	4.0	5.6	0.71 (0.06,8.26)	0.999
		Enlisted Ground.	1.6	2.4	0.68 (0.06,7.68)	0.999
18-14	Popliteal Pulses (Doppler) (Diabetics)	All	6.3	2.2	2.96 (0.89,9.82)	0.117
		Officer	10.9	0.0	--	--
		Enlisted Flyer	4.0	5.6	0.71 (0.06,8.26)	0.999
		Enlisted Ground.	3.2	2.4	1.38 (0.19,10.10)	0.999

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
18-15	Dorsalis Pedis Pulses (Doppler) (Diabetics)	All	16.9	12.3	1.45 (0.78,2.71)	0.312
		Officer	18.2	12.1	1.62 (0.57,4.61)	0.519
		Enlisted Flyer	12.0	16.7	0.68 (0.15,3.03)	0.890
		Enlisted Ground.	17.7	10.6	1.82 (0.70,4.71)	0.315
18-16	Posterior Tibial Pulses (Doppler) (Diabetics)	All	9.2	6.1	1.54 (0.67,3.55)	0.421
		Officer	12.7	5.2	2.67 (0.65,10.92)	0.279
		Enlisted Flyer	4.0	11.1	0.33 (0.03,3.18)	0.602
		Enlisted Ground.	8.1	4.7	1.78 (0.46,6.91)	0.624
18-17	Leg Pulses (Doppler) (Diabetics)	All	18.3	13.4	1.45 (0.79,2.65)	0.295
		Officer	18.2	12.1	1.62 (0.56,4.61)	0.519
		Enlisted Flyer	12.0	19.4	0.56 (0.13,2.44)	0.674
		Enlisted Ground.	21.0	11.8	1.99 (0.81,4.89)	0.198
18-18	Peripheral Pulses (Doppler) (Diabetics)	All	19.0	14.0	1.45 (0.80,2.62)	0.286
		Officer	20.0	13.8	1.56 (0.58,4.23)	0.529
		Enlisted Flyer	12.0	19.4	0.56 (0.13,2.44)	0.674
		Enlisted Ground.	21.0	11.8	1.99 (0.81,4.89)	0.198
18-20	Thyroid Stimulating Hormone (TSH)	All	2.4	2.3	1.01 (0.57,1.76)	0.999
		Officer	2.2	3.5	0.62 (0.27,1.46)	0.374
		Enlisted Flyer	2.5	1.0	2.55 (0.46,14.08)	0.488
		Enlisted Ground.	2.4	1.8	1.35 (0.56,3.27)	0.663
18-22	Thyroxine (T ₄)	All	0.6	0.6	1.00 (0.34,2.88)	0.999
		Officer	1.4	1.0	1.35 (0.39,4.70)	0.880
		Enlisted Flyer	0.6	0.0	--	--
		Enlisted Ground.	0.0	0.5	--	--
18-23	Anti-Thyroid Antibodies	All	3.9	2.4	1.62 (0.99,2.64)	0.071
		Officer	3.9	2.9	1.36 (0.64,2.89)	0.545
		Enlisted Flyer	4.4	1.5	3.01 (0.77,11.85)	0.183
		Enlisted Ground.	3.6	2.3	1.57 (0.74,3.33)	0.325
18-25	Fasting Glucose (All Participants)	All	13.4	13.1	1.03 (0.80,1.31)	0.891
		Officer	13.2	12.5	1.06 (0.71,1.58)	0.874
		Enlisted Flyer	14.2	14.9	0.95 (0.53,1.71)	0.979
		Enlisted Ground.	13.2	12.9	1.03 (0.71,1.49)	0.956
18-27	Fasting Glucose (Diabetics)	All	69.0	69.3	0.99 (0.61,1.59)	0.999
		Officer	69.1	74.1	0.78 (0.34,1.77)	0.699
		Enlisted Flyer	76.0	66.7	1.58 (0.50,5.00)	0.617
		Enlisted Ground.	66.1	67.1	0.96 (0.48,1.92)	0.999

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
18-29	Fasting Glucose (Nondiabetics)	All	3.6	3.9	0.91 (0.57,1.48)	0.804
		Officer	3.2	4.5	0.71 (0.33,1.53)	0.487
		Enlisted Flyer	2.9	3.6	0.80 (0.22,2.90)	0.989
		Enlisted Ground.	4.2	3.6	1.20 (0.59,2.44)	0.745
18-31	2-Hour Postprandial Glucose (Nondiabetics)	All	14.7	12.0	1.26 (0.97,1.65)	0.097
		Officer	12.6	10.1	1.28 (0.81,2.01)	0.351
		Enlisted Flyer	15.3	16.3	0.93 (0.59,1.73)	0.949
		Enlisted Ground.	16.4	12.3	1.39 (0.95,2.06)	0.113
18-32	Fasting Urinary Glucose (All Participants)	All	3.1	3.1	1.00 (0.61,1.63)	0.999
		Officer	2.5	2.8	0.88 (0.38,2.06)	0.938
		Enlisted Flyer	3.1	4.5	0.69 (0.23,2.09)	0.697
		Enlisted Ground.	3.6	2.8	1.28 (0.63,2.62)	0.621
18-33	Fasting Urinary Glucose (Diabetics)	All	20.4	21.3	0.95 (0.55,1.63)	0.949
		Officer	16.4	24.1	0.61 (0.24,1.56)	0.428
		Enlisted Flyer	20.0	22.2	0.88 (0.25,3.07)	0.999
		Enlisted Ground.	24.2	19.0	1.36 (0.61,3.01)	0.585
18-34	Fasting Urinary Glucose (Nondiabetics)	All	0.0	0.1	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.6	--	--
		Enlisted Ground.	0.0	0.0	--	--
18-35	2-Hour Postprandial Urinary Glucose (Nondiabetics)	All	18.6	18.3	1.02 (0.81,1.29)	0.895
		Officer	14.9	13.8	1.10 (0.73,1.66)	0.731
		Enlisted Flyer	20.4	22.9	0.87 (0.50,1.50)	0.708
		Enlisted Ground.	21.1	20.8	1.02 (0.73,1.42)	0.992
18-39	Serum Insulin (Diabetics)	All	60.6	55.9	1.21 (0.77,1.90)	0.472
		Officer	74.5	62.1	1.79 (0.80,4.01)	0.222
		Enlisted Flyer	52.0	52.9	0.96 (0.34,2.71)	0.999
		Enlisted Ground.	51.6	52.9	0.95 (0.49,1.83)	0.999
18-43	Serum Glucagon (All Participants)	All	0.4	0.1	4.02 (0.42,38.68)	0.426
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.8	0.2	4.01 (0.42,38.75)	0.428
18-45	Serum Glucagon (Diabetics)	All	2.4	0.6	3.91 (0.40,38.05)	0.449
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	5.6	1.4	4.29 (0.43,42.46)	0.403

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
18-47	Serum Glucagon (Nondiabetics)	All	0.0	0.0	--	--
		Officer	0.0	0.0	--	--
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.0	--	--
18-49	α -1-C Hemoglobin (All Participants)	All	26.9	26.3	1.03 (0.85,1.25)	0.774
		Officer	24.1	22.5	1.09 (0.80,1.50)	0.639
		Enlisted Flyer	30.2	35.6	0.78 (0.50,1.22)	0.330
		Enlisted Ground.	28.1	26.4	1.09 (0.83,1.45)	0.581
18-51	α -1-C Hemoglobin (Diabetics)	All	79.6	76.5	1.20 (0.70,2.04)	0.605
		Officer	78.2	75.9	1.14 (0.47,2.74)	0.945
		Enlisted Flyer	80.0	80.6	0.97 (0.27,3.48)	0.999
		Enlisted Ground.	80.6	75.3	1.37 (0.61,3.04)	0.570
18-53	α -1-C Hemoglobin (Nondiabetics)	All	17.7	18.1	0.97 (0.77,1.23)	0.858
		Officer	14.5	15.5	0.92 (0.61,1.39)	0.777
		Enlisted Flyer	21.2	25.9	0.77 (0.45,1.31)	0.407
		Enlisted Ground.	19.1	17.8	1.09 (0.77,1.55)	0.698
18-54	Urinary Protein (Diabetics)	All	12.7	15.2	0.81 (0.43,1.54)	0.635
		Officer	12.7	12.1	1.06 (0.35,3.25)	0.999
		Enlisted Flyer	12.0	11.1	1.09 (0.22,5.36)	0.999
		Enlisted Ground.	12.9	19.1	0.63 (0.25,1.58)	0.445
18-56	Serum Proinsulin (Diabetics)	All	41.0	42.8	0.93 (0.59,1.47)	0.851
		Officer	36.5	43.9	0.74 (0.34,1.59)	0.560
		Enlisted Flyer	39.1	42.9	0.86 (0.29,2.50)	0.993
		Enlisted Ground.	45.8	42.0	1.17 (0.59,2.29)	0.784
18-58	Serum C Peptide (Diabetics)	All	61.2	61.3	1.00 (0.63,1.59)	0.999
		Officer	63.5	64.9	0.94 (0.43,2.06)	0.999
		Enlisted Flyer	56.5	54.3	1.09 (0.38,3.16)	0.999
		Enlisted Ground.	61.0	61.7	0.97 (0.49,1.93)	0.999
18-60	Total Testosterone	All	4.6	5.4	0.85 (0.58,1.26)	0.481
		Officer	4.8	4.6	1.04 (0.55,1.97)	0.999
		Enlisted Flyer	3.7	5.5	0.67 (0.24,1.84)	0.589
		Enlisted Ground.	4.8	6.0	0.79 (0.45,1.40)	0.510
18-62	Free Testosterone	All	15.4	19.5	0.75 (0.60,0.94)	0.014
		Officer	15.1	19.0	0.76 (0.53,1.10)	0.166
		Enlisted Flyer	8.7	18.5	0.42 (0.22,0.81)	0.012
		Enlisted Ground.	18.2	20.3	0.87 (0.63,1.20)	0.449

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
18-63	Sex Hormone Binding Globulin	All	15.6	18.9	0.79 (0.63,0.99)	0.051
		Officer	17.6	19.6	0.88 (0.62,1.25)	0.527
		Enlisted Flyer	13.7	16.5	0.80 (0.45,1.44)	0.550
		Enlisted Ground.	14.6	19.1	0.72 (0.51,1.02)	0.077
18-64	Total Testosterone to Sex Hormone Binding Globulin Ratio	All	9.1	10.5	0.85 (0.64,1.14)	0.351
		Officer	9.2	11.8	0.76 (0.49,1.19)	0.280
		Enlisted Flyer	9.3	12.5	0.72 (0.37,1.42)	0.430
		Enlisted Ground.	8.9	8.6	1.03 (0.66,1.62)	0.972
18-66	Estradiol	All	3.8	4.0	0.95 (0.61,1.46)	0.893
		Officer	2.7	4.0	0.68 (0.31,1.46)	0.414
		Enlisted Flyer	4.9	5.0	1.00 (0.38,2.59)	0.999
		Enlisted Ground.	4.3	3.6	1.17 (0.62,2.23)	0.744
18-68	Luteinizing Hormone (LH)	All	1.7	2.0	0.82 (0.44,1.55)	0.656
		Officer	1.4	2.8	0.48 (0.17,1.35)	0.236
		Enlisted Flyer	2.5	2.0	1.25 (0.31,5.09)	0.999
		Enlisted Ground.	1.7	1.4	1.20 (0.43,3.32)	0.938
18-70	Follicle Stimulating Hormone	All	4.9	3.8	1.30 (0.87,1.96)	0.241
		Officer	7.1	4.0	1.85 (1.02,3.37)	0.062
		Enlisted Flyer	6.2	5.0	1.26 (0.51,3.11)	0.782
		Enlisted Ground.	2.6	3.3	0.78 (0.37,1.65)	0.652
19-4	Composite Skin Test Diagnosis	All	4.2	3.0	1.46 (0.92,2.31)	0.136
		Officer	5.4	2.9	1.87 (0.92,3.78)	0.113
		Enlisted Flyer	3.8	3.1	1.22 (0.39,3.87)	0.961
		Enlisted Ground.	3.4	2.9	1.20 (0.58,2.48)	0.769
19-15	Double Labelled Cells: CD5 with CD20 (Zero vs. Nonzero)	All	5.2	4.4	1.20 (0.64,2.26)	0.693
		Officer	6.5	6.2	1.04 (0.43,2.52)	0.999
		Enlisted Flyer	3.0	4.8	0.62 (0.11,3.48)	0.895
		Enlisted Ground.	4.8	2.7	1.81 (0.60,5.49)	0.441
19-16	Double Labelled Cells: CD4 with CD8 (Zero vs. Nonzero)	All	10.6	10.6	1.01 (0.65,1.56)	0.999
		Officer	11.0	10.2	1.09 (0.54,2.20)	0.952
		Enlisted Flyer	9.1	4.8	1.98 (0.53,7.31)	0.480
		Enlisted Ground.	10.9	13.0	0.82 (0.43,1.56)	0.654
19-17	Double Labelled Cells: CD3 with CD16+56 (Zero vs. Nonzero)	All	3.8	3.1	1.24 (0.59,2.59)	0.713
		Officer	3.9	4.5	0.85 (0.29,2.51)	0.985
		Enlisted Flyer	1.5	1.2	1.26 (0.08,20.56)	0.999
		Enlisted Ground.	4.8	2.7	1.81 (0.60,5.49)	0.441

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
19-22	Lupus Panel: Antinuclear Antibody (ANA)	All	13.7	16.4	0.81 (0.64,1.03)	0.092
		Officer	15.7	17.9	0.86 (0.59,1.23)	0.454
		Enlisted Flyer	16.3	16.5	0.98 (0.56,1.72)	0.999
		Enlisted Ground.	10.9	15.0	0.69 (0.47,1.02)	0.073
19-23	Lupus Panel: Thyroid Microsomal Antibody	All	4.4	2.8	1.61 (1.02,2.55)	0.054
		Officer	4.1	3.5	1.20 (0.59,2.45)	0.739
		Enlisted Flyer	5.0	1.5	3.46 (0.90,13.25)	0.108
		Enlisted Ground.	4.4	2.6	1.69 (0.84,3.40)	0.189
19-24	Lupus Panel: MSK Smooth Muscle Antibody	All	3.0	3.2	0.94 (0.58,1.54)	0.914
		Officer	4.7	3.7	1.29 (0.66,2.55)	0.567
		Enlisted Flyer	1.9	2.5	0.75 (0.18,3.17)	0.968
		Enlisted Ground.	1.9	3.0	0.65 (0.28,1.51)	0.416
19-25	Lupus Panel: MSK Mitochondrial Antibody	All	0.2	0.2	0.90 (0.15,5.40)	0.999
		Officer	0.6	0.2	2.72 (0.25,30.12)	0.791
		Enlisted Flyer	0.0	0.0	--	--
		Enlisted Ground.	0.0	0.3	0.28 (0.01,5.76)	0.627
19-26	Lupus Panel: MSK Parietal Antibody	All	2.4	2.6	0.90 (0.52,1.55)	0.804
		Officer	3.0	2.0	1.51 (0.63,3.59)	0.479
		Enlisted Flyer	1.9	2.0	0.94 (0.21,4.25)	0.999
		Enlisted Ground.	1.9	3.3	0.58 (0.25,1.33)	0.265
19-27	Lupus Panel: Rheumatoid Factor	All	15.2	16.7	0.89 (0.71,1.13)	0.367
		Officer	15.2	19.5	0.74 (0.51,1.06)	0.118
		Enlisted Flyer	13.8	17.0	0.78 (0.44,1.39)	0.484
		Enlisted Ground.	15.7	14.2	1.13 (0.80,1.61)	0.551
19-28	Lupus Panel: B Cell Clones Detected by Serum Protein Electrophoresis	All	2.4	1.7	1.36 (0.75,2.47)	0.392
		Officer	3.3	1.6	2.07 (0.84,5.11)	0.168
		Enlisted Flyer	3.8	3.0	1.26 (0.40,3.98)	0.922
		Enlisted Ground.	1.0	1.4	0.69 (0.21,2.31)	0.754
19-29	Lupus Panel: Other Antibodies (ANA and MSK)	All	3.1	4.0	0.76 (0.48,1.21)	0.300
		Officer	3.0	4.7	0.64 (0.31,1.32)	0.297
		Enlisted Flyer	4.4	5.0	0.88 (0.33,2.35)	0.988
		Enlisted Ground.	2.7	3.2	0.85 (0.40,1.81)	0.808
19-30	Lupus Panel: Summary Index	All	37.1	40.1	0.88 (0.74,1.05)	0.170
		Officer	41.0	43.7	0.90 (0.68,1.18)	0.481
		Enlisted Flyer	38.4	39.0	0.97 (0.64,1.49)	0.989
		Enlisted Ground.	33.1	37.3	0.83 (0.64,1.09)	0.196

Table Q-1-5. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 1: Ranch Hands versus Comparisons

Table Ref.	Clinical Parameter	Occupational Category	Percent Abnormal		Est. Relative Risk (95% C.I.)	p-Value
			RH	C		
20-3	Asthma	All	3.9	2.7	1.49 (0.93,2.39)	0.124
		Officer	4.4	2.6	1.72 (0.82,3.63)	0.209
		Enlisted Flyer	1.9	2.0	0.95 (0.21,4.29)	0.999
		Enlisted Ground.	4.3	3.0	1.47 (0.75,2.88)	0.346
20-4	Bronchitis	All	19.4	16.6	1.21 (0.97,1.51)	0.098
		Officer	15.8	15.9	1.00 (0.68,1.45)	0.999
		Enlisted Flyer	26.9	17.2	1.78 (1.07,2.96)	0.037
		Enlisted Ground.	19.7	17.0	1.20 (0.86,1.66)	0.319
20-5	Pneumonia	All	8.5	12.0	0.68 (0.51,0.92)	0.012
		Officer	8.4	13.5	0.59 (0.37,0.93)	0.029
		Enlisted Flyer	11.3	11.3	1.00 (0.51,1.95)	0.999
		Enlisted Ground.	7.6	10.9	0.67 (0.43,1.06)	0.108
20-6	Thorax and Lung Abnormalities	All	14.2	10.5	1.40 (1.09,1.81)	0.011
		Officer	10.1	7.4	1.41 (0.88,2.27)	0.197
		Enlisted Flyer	22.8	12.3	2.11 (1.21,3.68)	0.012
		Enlisted Ground.	14.4	12.7	1.16 (0.81,1.67)	0.480
20-7	X Ray Interpretation	All	13.5	13.4	1.00 (0.78,1.28)	0.999
		Officer	12.3	12.6	0.97 (0.65,1.47)	0.982
		Enlisted Flyer	19.1	14.3	1.42 (0.82,2.47)	0.271
		Enlisted Ground.	12.3	13.9	0.87 (0.60,1.27)	0.531

--: Estimated relative risk, confidence interval, and p-value not presented due to the sparse number of abnormalities.

Note: RH = Ranch Hand
C = Comparison.

Table Q-1-6.
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands -- Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
9-3	Self-Perception of Health	1.21 (1.00,1.46)	0.049
9-4	Appearance of Illness or Distress	0.90 (0.57,1.43)	0.648
9-5	Relative Age Appearance	1.29 (0.98,1.68)	0.070
9-8	Body Fat	0.99 (0.80,1.24)	0.950
9-9	Body Fat with Adjustment for Caloric Intake	0.99 (0.80,1.24)	0.950
9-11	Sedimentation Rate	1.02 (0.87,1.19)	0.835
10-3	Skin Neoplasms	0.77 (0.66,0.90)	<0.001
10-4	Malignant Skin Neoplasms	0.74 (0.59,0.93)	0.006
10-5	Benign Skin Neoplasms	0.86 (0.72,1.02)	0.085
10-6	Skin Neoplasms of Uncertain Behavior or Unspecified Nature	0.72 (0.24,2.15)	0.530
10-7	Basal Cell Carcinomas (All Sites Combined)	0.75 (0.59,0.95)	0.013
10-8	Basal Cell Carcinomas (Ear, Face, Head, and Neck)	0.73 (0.55,0.96)	0.017
10-9	Basal Cell Carcinomas (Trunk)	0.76 (0.52,1.11)	0.134
10-10	Basal Cell Carcinomas (Upper Extremities)	0.59 (0.31,1.13)	0.082
10-11	Basal Cell Carcinomas (Lower Extremities)	--	--
10-12	Squamous Cell Carcinomas	0.85 (0.43,1.70)	0.641
10-13	Nonmelanomas	0.74 (0.58,0.93)	0.007
10-14	Melanomas	0.61 (0.30,1.24)	0.136
10-15	Systemic Neoplasms	0.93 (0.79,1.09)	0.354
10-16	Malignant Systemic Neoplasms	0.63 (0.44,0.89)	0.004
10-17	Benign Systemic Neoplasms	1.02 (0.86,1.22)	0.804
10-18	Systemic Neoplasms of Uncertain Behavior or Unspecified Nature	0.91 (0.54,1.52)	0.709
10-19	Malignant Systemic Neoplasms (Eye, Ear, Face, Head, and Neck)	0.65 (0.32,1.30)	0.182
10-20	Malignant Systemic Neoplasms (Oral Cavity, Pharynx, and Larynx)	1.17 (0.52,2.62)	0.706
10-21	Malignant Systemic Neoplasms (Esophagus)	--	--
10-22	Malignant Systemic Neoplasms (Brain)	--	--

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands -- Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
10-23	Malignant Systemic Neoplasms (Thymus, Heart, and Mediastinum)	--	--
10-24	Malignant Systemic Neoplasms (Thyroid Gland)	0.14 (0.01,2.34)	0.044
10-25	Malignant Systemic Neoplasms (Bronchus and Lung)	0.61 (0.23,1.63)	0.275
10-26	Malignant Systemic Neoplasms (Colon and Rectum)	0.61 (0.24,1.55)	0.245
10-27	Malignant Systemic Neoplasms (Kidney and Bladder)	0.68 (0.28,1.65)	0.359
10-28	Malignant Systemic Neoplasms (Prostate)	0.68 (0.39,1.19)	0.147
10-29	Malignant Systemic Neoplasms (Testicles)	0.65 (0.22,1.95)	0.408
10-30	Malignant Systemic Neoplasms (Ill-Defined Sites)	--	--
10-31	Malignant Systemic Neoplasms (Connective and Other Soft Tissue)	--	--
10-32	Carcinomas in Situ of the Penis, Other, and Unspecified Sites	0.11 (0.00,9.47)	0.144
10-33	Hodgkin's Disease	--	--
10-34	Leukemia	0.61 (0.09,4.14)	0.569
10-35	Non-Hodgkin's Lymphoma	--	--
10-36	Other Malignant Systemic Neoplasms of Lymphoid and Histiocytic Tissue	--	--
10-37	Multiple Myeloma	--	--
10-38	Skin or Systemic Neoplasms	0.84 (0.73,0.97)	0.012
10-39	Prostate-Specific Antigen (Below vs. At or Above Sensitivity Limit)	0.89 (0.57,1.40)	0.608
10-41	Prostate-Specific Antigen	0.61 (0.41,0.90)	0.006
11-3	Inflammatory Diseases	1.09 (0.51,2.35)	0.826
11-4	Hereditary and Degenerative Diseases	0.95 (0.70,1.28)	0.712
11-5	Peripheral Disorders	1.04 (0.88,1.23)	0.673
11-6	Other Neurological Disorders	1.08 (0.93,1.25)	0.323
11-7	Smell	0.69 (0.31,1.55)	0.341
11-8	Visual Fields	--	--
11-9	Light Reaction	1.43 (0.64,3.20)	0.384
11-10	Ocular Movement	0.80 (0.39,1.67)	0.542

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
11-11	Facial Sensation	1.53 (0.60,3.92)	0.382
11-12	Jaw Clench	--	--
11-13	Smile	1.29 (0.75,2.22)	0.363
11-14	Palpebral Fissure	1.05 (0.56,1.98)	0.876
11-15	Balance	1.14 (0.51,2.51)	0.757
11-16	Gag Reflex	--	--
11-17	Speech	1.11 (0.54,2.26)	0.777
11-18	Palate and Uvula Movement	--	--
11-19	Neck Range of Motion	0.91 (0.76,1.10)	0.340
11-20	Cranial Nerve Index Without Range of Motion	1.08 (0.80,1.46)	0.619
11-21	Pin Prick	0.97 (0.74,1.27)	0.832
11-22	Light Touch	0.97 (0.72,1.29)	0.821
11-23	Muscle Status	0.98 (0.67,1.42)	0.905
11-24	Patellar Reflex	0.93 (0.58,1.48)	0.756
11-25	Achilles Reflex	0.95 (0.77,1.18)	0.634
11-26	Biceps Reflex	0.47 (0.21,1.06)	0.030
11-27	Babinski Reflex	--	--
11-30	Tremor	1.28 (0.85,1.94)	0.244
11-31	Coordination	0.90 (0.58,1.39)	0.622
11-32	Romberg Sign	1.14 (0.51,2.51)	0.757
11-33	Gait	1.10 (0.78,1.56)	0.598
11-34	Central Nervous System (CNS) Index	1.10 (0.84,1.45)	0.501
12-3	Psychoses	0.91 (0.62,1.33)	0.604
12-4	Alcohol Dependence	1.05 (0.81,1.35)	0.722
12-5	Drug Dependence	--	--
12-6	Anxiety	1.14 (0.96,1.35)	0.139
12-7	Other Neuroses	1.04 (0.92,1.19)	0.518
12-8	SCL-90-R Anxiety	1.11 (0.90,1.39)	0.335
12-9	SCL-90-R Depression	1.16 (0.95,1.42)	0.148
12-10	SCL-90-R Hostility	1.26 (0.99,1.60)	0.067
12-11	SCL-90-R Interpersonal Sensitivity	1.09 (0.90,1.33)	0.381

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
12-12	SCL-90-R Obsessive-Compulsive Behavior	1.11 (0.91,1.36)	0.304
12-13	SCL-90-R Paranoid Ideation	1.06 (0.82,1.36)	0.652
12-14	SCL-90-R Phobic Anxiety	1.27 (1.02,1.58)	0.036
12-15	SCL-90-R Psychoticism	1.06 (0.86,1.32)	0.587
12-16	SCL-90-R Somatization	1.16 (0.95,1.41)	0.158
12-17	SCL-90-R Global Severity Index	1.17 (0.96,1.43)	0.121
12-18	SCL-90-R Positive Symptom Total	1.14 (0.94,1.38)	0.177
12-19	SCL-90-R Positive Symptom Distress Index	1.14 (0.91,1.43)	0.248
13-3	Hepatitis (Non-A, Non-B, and Non-C)	1.11 (0.67,1.83)	0.693
13-4	Jaundice	1.15 (0.52,2.53)	0.739
13-5	Acute and Subacute Necrosis of the Liver	--	--
13-6	Alcoholic Chronic Liver Disease and Cirrhosis	1.05 (0.79,1.39)	0.759
13-7	Nonalcoholic Chronic Liver Disease and Cirrhosis	0.98 (0.55,1.72)	0.932
13-8	Liver Abscess and Sequelae of Chronic Liver Disease	--	--
13-9	Other Liver Disorders	1.10 (0.96,1.27)	0.177
13-10	Hepatomegaly	1.01 (0.61,1.67)	0.980
13-11	Current Hepatomegaly	0.83 (0.38,1.81)	0.632
13-13	AST	1.03 (0.69,1.52)	0.895
13-15	ALT	1.17 (0.91,1.51)	0.221
13-17	GGT	1.05 (0.89,1.22)	0.574
13-19	Alkaline Phosphatase	1.07 (0.81,1.41)	0.631
13-21	Total Bilirubin	0.97 (0.71,1.33)	0.844
13-22	Direct Bilirubin	0.73 (0.36,1.46)	0.348
13-24	LDH	1.10 (0.92,1.32)	0.302
13-26	Cholesterol	1.01 (0.84,1.21)	0.926
13-28	HDL Cholesterol	1.07 (0.87,1.32)	0.517
13-30	Cholesterol-HDL Ratio	1.13 (0.98,1.30)	0.081
13-32	Triglycerides	1.13 (0.93,1.37)	0.211
13-34	Creatine Kinase	1.01 (0.84,1.21)	0.914

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
13-36	Serum Amylase	0.82 (0.60,1.12)	0.189
13-37	Antibodies for Hepatitis A	0.99 (0.86,1.13)	0.864
13-38	Serological Evidence of Present or Prior Hepatitis B Infection	1.21 (1.00,1.48)	0.054
13-39	Antibodies for Hepatitis C	0.42 (0.08,2.18)	0.229
13-40	Stool Hemocult	0.80 (0.51,1.26)	0.313
13-42	Prealbumin	1.38 (0.77,2.49)	0.282
13-44	Albumin	1.11 (0.76,1.62)	0.599
13-46	α -1 Acid Glycoprotein	1.17 (0.74,1.85)	0.507
13-50	α -2 Macroglobulin	1.38 (0.53,3.59)	0.508
13-52	Apolipoprotein B	1.08 (0.93,1.26)	0.310
13-54	C ₃ Complement	0.83 (0.47,1.46)	0.504
13-56	C ₄ Complement	1.20 (0.56,2.58)	0.644
13-58	Haptoglobin	1.05 (0.87,1.27)	0.617
13-60	Transferrin	0.91 (0.72,1.14)	0.403
14-3	Occurrence of Acne (Lifetime)	0.93 (0.77,1.13)	0.487
14-4	Acne Relative to Time of Duty in SEA (Pre- and Post-SEA and Post-SEA vs. Pre-SEA and None)	0.94 (0.78,1.13)	0.497
14-5	Acne Relative to Time of Duty in SEA (Post-SEA vs. None)	0.92 (0.76,1.12)	0.430
14-6	Acne Relative to Time of Duty in SEA (Pre- and Post-SEA vs. Pre-SEA)	1.20 (0.44,3.29)	0.705
14-8	Location of Acne (Post-SEA)	0.96 (0.82,1.11)	0.551
14-10	Location of Acne (Pre- and Post-SEA and Post-SEA)	1.02 (0.88,1.17)	0.804
14-11	Other Abnormalities	0.90 (0.75,1.07)	0.216
14-12	Dermatology Index	1.03 (0.90,1.18)	0.673
15-3	Verified Essential Hypertension	1.08 (0.94,1.24)	0.304
15-4	Verified Heart Disease (excluding Essential Hypertension)	0.85 (0.74,0.98)	0.019
15-5	Myocardial Infarction	1.04 (0.81,1.33)	0.772
15-7	Systolic Blood Pressure	0.97 (0.81,1.15)	0.691
15-8	Heart Sounds	0.96 (0.82,1.13)	0.648
15-9	Overall Electrocardiograph	0.88 (0.75,1.04)	0.127

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
15-10	ECG: Right Bundle Branch Block (RBBB)	1.09 (0.68,1.75)	0.720
15-11	ECG: Left Bundle Branch Block (LBBB)	--	--
15-12	ECG: Nonspecific ST- and T-Wave Changes	0.91 (0.76,1.10)	0.336
15-13	ECG: Bradycardia	0.66 (0.37,1.15)	0.108
15-14	ECG: Tachycardia	--	--
15-15	ECG: Arrhythmia	0.96 (0.72,1.27)	0.759
15-16	ECG: Evidence of Prior Myocardial Infarction	1.18 (0.85,1.65)	0.326
15-17	ECG: Other Diagnoses	1.36 (0.78,2.38)	0.288
15-19	Diastolic Blood Pressure	1.19 (0.83,1.70)	0.343
15-20	Funduscopic Examination	1.17 (0.93,1.48)	0.193
15-21	Carotid Bruits	0.79 (0.45,1.37)	0.382
15-22	Radial Pulses	0.34 (0.06,1.98)	0.124
15-23	Femoral Pulses	0.59 (0.31,1.13)	0.076
15-24	Popliteal Pulses	0.85 (0.56,1.29)	0.430
15-25	Dorsalis Pedis Pulses	1.02 (0.81,1.28)	0.892
15-26	Posterior Tibial Pulses	0.82 (0.58,1.17)	0.260
15-27	Leg Pulses	1.01 (0.81,1.26)	0.930
15-28	Peripheral Pulses	1.01 (0.81,1.26)	0.930
15-29	Kidney, Urethra, and Bladder (KUB) X Ray (Excluding Kidney Stones)	1.00 (0.86,1.15)	0.961
15-30	Intermittent Claudication and Vascular Insufficiency (ICVI) Index	1.02 (0.72,1.46)	0.899
16-10	Hematocrit	1.22 (0.74,2.01)	0.439
16-12	Platelet Count	1.38 (0.88,2.16)	0.174
16-14	Prothrombin Time	0.47 (0.16,1.38)	0.101
16-15	RBC Morphology	0.97 (0.85,1.11)	0.681
16-17	Absolute Neutrophils (bands) (Zero versus Nonzero)	0.92 (0.76,1.10)	0.332
16-20	Absolute Eosinophils (Zero versus Nonzero)	1.05 (0.86,1.29)	0.625
16-21	Absolute Basophils (Zero versus Nonzero)	0.97 (0.85,1.11)	0.669

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
17-3	Kidney Disease	0.97 (0.81,1.15)	0.717
17-4	Kidney Stones	0.58 (0.36,0.94)	0.016
17-5	Urinary Protein	1.18 (0.87,1.59)	0.287
17-6	Urinary Red Blood Cell Count	1.10 (0.79,1.52)	0.582
17-7	Urinary White Blood Cell Count	0.94 (0.66,1.34)	0.736
18-3	Past Thyroid Disease	1.08 (0.80,1.47)	0.621
18-4	Composite Diabetes Indicator	1.01 (0.85,1.19)	0.947
18-7	Thyroid Gland	--	--
18-10	Retinopathy Results (Diabetics)	1.59 (0.88,2.88)	0.144
18-11	Neuropathy Results (Diabetics)	1.20 (0.77,1.87)	0.421
18-12	Radial Pulses (Doppler) (Diabetics)	--	--
18-13	Femoral Pulses (Doppler) (Diabetics)	0.73 (0.34,1.55)	0.377
18-14	Popliteal Pulses (Doppler) (Diabetics)	0.90 (0.52,1.56)	0.699
18-15	Dorsalis Pedis Pulses (Doppler) (Diabetics)	1.19 (0.83,1.70)	0.351
18-16	Posterior Tibial Pulses (Doppler) (Diabetics)	0.84 (0.51,1.37)	0.463
18-17	Leg Pulses (Doppler) (Diabetics)	1.20 (0.85,1.70)	0.294
18-18	Peripheral Pulses (Doppler) (Diabetics)	1.20 (0.85,1.70)	0.294
18-20	Thyroid Stimulating Hormone (TSH)	1.44 (0.97,2.15)	0.076
18-22	Thyroxine (T ₄)	1.06 (0.43,2.57)	0.903
18-23	Anti-Thyroid Antibodies	0.92 (0.66,1.30)	0.644
18-25	Fasting Glucose (All participants)	0.96 (0.80,1.16)	0.690
18-27	Fasting Glucose (Diabetics)	0.96 (0.69,1.34)	0.830
18-29	Fasting Glucose (Nondiabetics)	0.83 (0.55,1.26)	0.372
18-31	2-Hour Postprandial Glucose (Nondiabetics)	1.09 (0.90,1.33)	0.390
18-32	Fasting Urinary Glucose (All participants)	1.39 (1.05,1.85)	0.023
18-33	Fasting Urinary Glucose (Diabetics)	1.43 (1.03,2.00)	0.031
18-34	Fasting Urinary Glucose (Nondiabetics)	--	--
18-35	2-Hour Postprandial Urinary Glucose (Nondiabetics)	1.18 (0.98,1.41)	0.074
18-39	Serum Insulin (Diabetics)	0.62 (0.44,0.87)	0.003
18-43	Serum Glucagon (All participants)	0.71 (0.22,2.32)	0.546

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
18-45	Serum Glucagon (Diabetics)	0.72 (0.22,2.37)	0.566
18-47	Serum Glucagon (Nondiabetics)	--	--
18-49	α -1-C Hemoglobin (All participants)	1.02 (0.88,1.18)	0.773
18-51	α -1-C Hemoglobin (Diabetics)	1.02 (0.66,1.57)	0.931
18-53	α -1-C Hemoglobin (Nondiabetics)	1.02 (0.83,1.24)	0.866
18-54	Urinary Protein (Diabetics)	1.21 (0.78,1.88)	0.401
18-56	Serum Proinsulin (Diabetics)	1.09 (0.81,1.46)	0.556
18-58	Serum C Peptide (Diabetics)	0.79 (0.56,1.09)	0.140
18-60	Total Testosterone	1.05 (0.80,1.38)	0.709
18-62	Free Testosterone	1.14 (0.96,1.36)	0.129
18-63	Sex Hormone Binding Globulin	0.99 (0.82,1.18)	0.871
18-64	Total Testosterone to Sex Hormone Binding Globulin Ratio	0.98 (0.79,1.22)	0.879
18-66	Estradiol	1.24 (0.91,1.68)	0.180
18-68	Luteinizing Hormone (LH)	1.46 (0.83,2.57)	0.202
18-70	Follicle Stimulating Hormone	0.97 (0.71,1.32)	0.822
19-4	Composite Skin Test Diagnosis	0.77 (0.49,1.22)	0.240
19-15	Double Labelled Cells: CD5 with CD20 (Zero vs. Nonzero)	0.72 (0.41,1.29)	0.248
19-16	Double Labelled Cells: CD4 with CD8 (Zero vs. Nonzero)	0.93 (0.65,1.33)	0.686
19-17	Double Labelled Cells: CD3 with CD16+56 (Zero vs. Nonzero)	1.60 (0.95,2.70)	0.070
19-22	Lupus Panel: Antinuclear Antibody (ANA)	0.95 (0.77,1.16)	0.599
19-23	Lupus Panel: Thyroid Microsomal Antibody	0.91 (0.67,1.24)	0.559
19-24	Lupus Panel: MSK Smooth Muscle Antibody	0.60 (0.36,1.00)	0.035
19-25	Lupus Panel: MSK Mitochondrial Antibody	--	--
19-26	Lupus Panel: MSK Parietal Antibody	0.88 (0.59,1.33)	0.533
19-27	Lupus Panel: Rheumatoid Factor	0.80 (0.65,0.98)	0.028
19-28	Lupus Panel: B Cell Clones Detected by Serum Protein Electrophoresis	1.05 (0.66,1.68)	0.838

Table Q-1-6. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 2: Ranch Hands – Log₂ (Initial Dioxin)

Table Reference	Clinical Parameter	Est. Relative Risk (95% C.I.) ^a	p-Value ^a
19-29	Lupus Panel: Other Antibodies (ANA and MSK)	1.15 (0.77,1.71)	0.508
19-30	Lupus Panel: Summary Index	0.88 (0.76,1.01)	0.067
20-3	Asthma	1.17 (0.84,1.62)	0.357
20-4	Bronchitis	1.00 (0.84,1.19)	0.979
20-5	Pneumonia	0.87 (0.67,1.14)	0.309
20-6	Thorax and Lung Abnormalities	1.11 (0.92,1.35)	0.284
20-7	X Ray Interpretation	0.93 (0.76,1.14)	0.490

^a Adjusted for percent body fat at the time of duty in SEA and change in percent body fat from the time of duty in SEA to the date of the blood draw for dioxin.

--: Estimated relative risk, confidence interval, and p-value not presented due to the sparse number of abnormalities.

Note: Relative risk for a twofold increase in initial dioxin.

Table Q-1-7.
Summary of Unadjusted Results for Dichotomous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter	Dioxin Category	n	Percent Abnormal	Est. Relative Risk (95% C.I.) ^{ab}	p-Value ^a
9-3	Self-Perception of Health	Comparison	1,061	7.0		
		Background RH	374	6.7	1.06 (0.66,1.70)	0.815
		Low RH	260	10.4	1.47 (0.92,2.34)	0.107
		High RH	260	15.0	2.20 (1.45,3.34)	<0.001
		Low plus High RH	520	12.7	1.82 (1.28,2.60)	0.001
9-4	Appearance of Illness or Distress	Comparison	1,063	1.5		
		Background RH	374	2.1	1.46 (0.61,3.47)	0.394
		Low RH	260	2.3	1.41 (0.54,3.66)	0.482
		High RH	260	1.5	0.95 (0.31,2.92)	0.924
		Low plus High RH	520	1.9	1.18 (0.53,2.66)	0.685
9-5	Relative Age Appearance	Comparison	1,063	6.2		
		Background RH	374	4.3	0.71 (0.40,1.24)	0.229
		Low RH	260	4.2	0.64 (0.33,1.23)	0.177
		High RH	260	7.7	1.22 (0.22,2.06)	0.460
		Low plus High RH	520	6.0	0.92 (0.59,1.43)	0.710
9-8	Body Fat	Comparison	1,063	26.3		
		Background RH	374	14.2	0.82 (0.49,1.35)	0.427
		Low RH	260	30.4	1.19 (0.75,1.90)	0.464
		High RH	260	35.8	1.23 (0.78,1.94)	0.377
		Low plus High RH	520	33.1	1.21 (0.84,1.73)	0.300
9-9	Body Fat with Adjustment for Caloric Intake	Comparison	1,063	26.3		
		Background RH	374	14.2	0.82 (0.49,1.35)	0.427
		Low RH	260	30.4	1.19 (0.75,1.90)	0.464
		High RH	260	35.8	1.23 (0.78,1.94)	0.377
		Low plus High RH	520	33.1	1.21 (0.84,1.73)	0.300
9-11	Sedimentation Rate	Comparison	1,063	17.2		
		Background RH	374	13.4	0.79 (0.56,1.11)	0.174
		Low RH	260	21.5	1.29 (0.92,1.81)	0.136
		High RH	260	20.4	1.17 (0.83,1.65)	0.373
		Low plus High RH	520	21.0	1.23 (0.94,1.61)	0.128
10-3	Skin Neoplasms	Comparison	1,002	28.3		
		Background RH	356	33.4	1.31 (1.01,1.70)	0.043
		Low RH	232	36.6	1.44 (1.06,1.94)	0.019
		High RH	245	23.3	0.75 (0.54,1.04)	0.083
		Low plus High RH	477	29.8	1.05 (0.82,1.34)	0.694
10-4	Malignant Skin Neoplasms	Comparison	1,002	11.7		
		Background RH	356	14.3	1.33 (0.93,1.90)	0.119
		Low RH	232	17.3	1.53 (1.03,2.26)	0.036
		High RH	245	8.2	0.65 (0.39,1.07)	0.089
		Low plus High RH	477	12.6	1.05 (0.75,1.47)	0.761

Table Q-1-7. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter	Dioxin Category	n	Percent Abnormal	Est. Relative Risk (95% C.I.) ^{ab}	p-Value ^a
10-5	Benign Skin Neoplasms	Comparison	1,056	17.6		
		Background RH	371	21.6	1.30 (0.97,1.75)	0.082
		Low RH	255	20.0	1.17 (0.83,1.66)	0.365
		High RH	258	16.7	0.92 (0.64,1.33)	0.661
		Low plus High RH	513	18.3	1.04 (0.79,1.38)	0.761
10-6	Skin Neoplasms of Uncertain Behavior or Unspecified Nature	Comparison	1,002	0.5		
		Background RH	356	0.6	1.30 (0.25,6.85)	0.760
		Low RH	232	0.4	0.79 (0.09,6.90)	0.830
		High RH	245	0.4	0.69 (0.08,6.09)	0.739
		Low plus High RH	477	0.4	0.74 (0.14,3.90)	0.719
10-7	Basal Cell Carcinomas (All Sites Combined)	Comparison	1,002	10.1		
		Background RH	356	11.8	1.25 (0.85,1.84)	0.254
		Low RH	232	14.7	1.48 (0.97,2.25)	0.066
		High RH	245	6.5	0.60 (0.35,1.04)	0.071
		Low plus High RH	477	10.5	1.01 (0.71,1.45)	0.948
10-8	Basal Cell Carcinomas (Ear, Face, Head, and Neck)	Comparison	1,002	7.6		
		Background RH	356	10.1	1.44 (0.94,2.19)	0.091
		Low RH	232	12.1	1.61 (1.02,2.56)	0.042
		High RH	245	4.5	0.56 (0.29,1.06)	0.076
		Low plus High RH	477	8.2	1.05 (0.70,1.58)	0.812
10-9	Basal Cell Carcinomas (Trunk)	Comparison	1,002	2.8		
		Background RH	356	3.1	1.16 (0.57,2.38)	0.676
		Low RH	232	4.7	1.64 (0.80,3.36)	0.176
		High RH	245	2.9	0.99 (0.42,2.30)	0.977
		Low plus High RH	477	3.8	1.31 (0.71,2.40)	0.389
10-10	Basal Cell Carcinomas (Upper Extremities)	Comparison	1,002	1.8		
		Background RH	356	2.3	1.14 (0.60,3.32)	0.428
		Low RH	232	1.7	0.89 (0.30,2.66)	0.829
		High RH	245	1.2	0.62 (0.18,2.14)	0.449
		Low plus High RH	477	1.5	0.75 (0.31,1.82)	0.523
10-11	Basal Cell Carcinomas (Lower Extremities)	Comparison	1,002	0.2		
		Background RH	356	0.3	1.95 (0.17,22.90)	0.596
		Low RH	232	0.0	--	--
		High RH	245	0.0	--	--
		Low plus High RH	477	0.0	--	--
10-12	Squamous Cell Carcinomas	Comparison	1,002	1.1		
		Background RH	356	1.7	1.59 (0.58,4.40)	0.367
		Low RH	232	1.7	1.54 (0.49,4.92)	0.461
		High RH	245	0.8	0.73 (0.16,3.32)	0.680
		Low plus High RH	477	1.3	1.12 (0.41,3.07)	0.820

Table Q-1-7. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter	Dioxin Category	n	Percent Abnormal	Est. Relative Risk (95% C.I.) ^{ab}	p-Value ^a
10-13	Nonmelanomas	Comparison	1,002	11.1		
		Background RH	356	13.5	1.32 (0.92,1.91)	0.134
		Low RH	232	16.4	1.52 (1.02,2.27)	0.042
		High RH	245	7.4	0.61 (0.36,1.03)	0.064
		Low plus High RH	477	11.7	1.03 (0.73,1.45)	0.869
10-14	Melanomas	Comparison	1,002	0.8		
		Background RH	356	0.8	1.05 (0.27,4.01)	0.948
		Low RH	232	2.2	2.79 (0.90,8.66)	0.076
		High RH	245	0.8	1.01 (0.21,4.84)	0.987
		Low plus High RH	477	1.5	1.86 (0.67,5.21)	0.235
10-15	Systemic Neoplasms	Comparison	1,062	20.7		
		Background RH	372	19.6	0.98 (0.72,1.32)	0.873
		Low RH	255	23.9	1.17 (0.85,1.62)	0.340
		High RH	259	19.7	0.91 (0.65,1.28)	0.594
		Low plus High RH	514	21.8	1.04 (0.80,1.34)	0.784
10-16	Malignant Systemic Neoplasms	Comparison	1,062	4.2		
		Background RH	372	4.0	1.03 (0.57,1.89)	0.914
		Low RH	255	8.2	1.87 (1.09,3.22)	0.024
		High RH	259	3.1	0.67 (0.31,1.45)	0.309
		Low plus High RH	514	5.6	1.26 (0.77,2.04)	0.356
10-17	Benign Systemic Neoplasms	Comparison	1,062	15.6		
		Background RH	372	16.1	1.07 (0.77,1.48)	0.689
		Low RH	255	16.5	1.05 (0.73,1.52)	0.795
		High RH	259	16.2	1.02 (0.71,1.48)	0.911
		Low plus High RH	514	16.3	1.04 (0.78,1.38)	0.812
10-18	Systemic Neoplasms of Uncertain Behavior or Unspecified Nature	Comparison	1,062	1.8		
		Background RH	372	1.6	0.94 (0.37,2.38)	0.890
		Low RH	255	2.0	1.08 (0.40,2.94)	0.877
		High RH	259	1.2	0.62 (0.18,2.13)	0.448
		Low plus High RH	514	1.6	0.85 (0.37,1.96)	0.698
10-19	Malignant Systemic Neoplasms (Eye, Ear, Face, Head, and Neck)	Comparison	1,062	0.6		
		Background RH	372	0.8	1.57 (0.38,6.39)	0.532
		Low RH	255	1.6	2.49 (0.69,8.98)	0.163
		High RH	259	0.8	1.21 (0.24,6.17)	0.820
		Low plus High RH	514	1.2	1.85 (0.58,5.86)	0.295

Table Q-1-7. (Continued)
Summary of Unadjusted Results for Dichotomous Variables
Model 3: Ranch Hands and Comparisons by Dioxin Category

Table Ref.	Clinical Parameter	Dioxin Category	n	Percent Abnormal	Est. Relative Risk (95% C.I.) ^{ab}	p-Value ^a
10-20	Malignant Systemic Neoplasms (Oral Cavity, Pharynx, and Larynx)	Comparison	1,062	0.5		
		Background RH	372	0.3	0.58 (0.07,5.08)	0.624
		Low RH	255	0.4	0.77 (0.09,6.65)	0.810
		High RH	259	0.8	1.55 (0.29,8.26)	0.605
		Low plus High RH	514	0.6	1.15 (0.27,4.94)	0.847
10-21	Malignant Systemic Neoplasms (Esophagus)	Comparison	1,062	0.1		
		Background RH	372	0.0	--	--
		Low RH	255	0.0	--	--
		High RH	259	0.0	--	--
		Low plus High RH	514	0.0	--	--
10-22	Malignant Systemic Neoplasms (Brain)	Comparison	1,062	0.0		
		Background RH	372	0.0	--	--
		Low RH	255	0.4	--	--
		High RH	259	0.0	--	--
		Low plus High RH	514	0.2	--	--
10-23	Malignant Systemic Neoplasms (Thymus, Heart, and Mediastinum)	Comparison	1,062	0.0		
		Background RH	372	0.3	--	--
		Low RH	255	0.0	--	--
		High RH	259	0.0	--	--
		Low plus High RH	514	0.0	--	--
10-24	Malignant Systemic Neoplasms (Thyroid Gland)	Comparison	1,062	0.0		
		Background RH	372	0.0	--	--
		Low RH	255	0.8	--	--
		High RH	259	0.0	--	--
		Low plus High RH	514	0.4	--	--
10-25	Malignant Systemic Neoplasms (Bronchus and Lung)	Comparison	1,062	0.4		
		Background RH	372	0.8	2.40 (0.51,11.28)	0.268
		Low RH	255	1.2	2.48 (0.53,11.59)	0.249
		High RH	259	0.0	--	--
		Low plus High RH	514	0.6	1.06 (0.21,5.27)	0.944
10-26	Malignant Systemic Neoplasms (Colon and Rectum)	Comparison	1,062	0.3		
		Background RH	372	0.3	1.14 (0.12,11.07)	0.910
		Low RH	255	1.6	5.12 (1.13,23.27)	0.034
		High RH	259	0.0	--	--
		Low plus High RH	514	0.8	2.48 (0.55,11.23)	0.239
10-27	Malignant Systemic Neoplasms (Kidney and Bladder)	Comparison	1,062	0.4		
		Background RH	372	0.5	1.47 (0.26,8.19)	0.261
		Low RH	255	1.2	3.01 (0.66,13.61)	0.154
		High RH	259	0.4	1.00 (0.11,9.10)	0.997
		Low plus High RH	514	0.8	2.01 (0.50,8.14)	0.328